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INTRODUCTION 
 
 
The hypertensive disorders of pregnancy remain a leading cause of maternal and perinatal 
morbidity and mortality in Europe and North America. These disease challenge the 
medical and obstetric skills of the health care team. Decision as to the possible use and 
appropriate choice of pharmacologic agents require not only an understanding of the 
pathophysiology of the hypertensive disorders and a recognition of the pharmacokinetic 
changes occurring during pregnancy but also an appreciation of the possible fetal effects 
of such therapeutic agents. 
Obstetric management demands meticulous maternal observation and use of tests of fetal-
placental function and fetal maturity in order to weigh maternal risks and the risks to the 
infant of intrauterine versus extrauterine existence. The management of elevated blood 
pressure and the impact of the disorder on the mother and fetus depend on whether 
hypertension antedated the pregnancy or appeared as the marker of pregnancy-specific 
vasospastic syndrome. The hypertensive disorders of pregnancy were for many years 
called toxemias of pregnancy, a term that originally included even hyperemesis 
gravidarum and acute yellow atrophy of the liver. One of the difficulties in interpreting 
studies of the hypertensive disorders of pregnancy is the inconsistency of terminology. 
Several systems of nomenclature are used around the world.  The system prepared by the 
National Institutes of Health (NIH) working group on hypertension in pregnancy (1) 
although as imperfect as all such systems, has the advantage of clarity and is available in 
published form to investigators throughout the world.  
This classification is as follows: 
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1) Chronic hypertension 
2) Preeclampsia-eclampsia 
3) Preeclampsia superimposed upon chronic hypertension 
4) Gestational hypertension 
 
For mild-to-moderate pregnancy hypertension, maternal risks are small, and there may be 
adverse perinatal consequences of blood pressure normalization. 
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Chronic hypertension 
Chronic hypertension is defined as hypertension that is present and observable prior to 
pregnancy or that is diagnosed before the 20th week of gestation. Hypertension is defined 
as a blood pressure greater than 140/90 mmHg. Hypertension for which a diagnosis is 
confirmed for the first time during pregnancy and which persist beyond the 84th day 
postpartum is also classified as chronic hypertension. 
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Preeclampsia and eclampsia 
 
The diagnosis of preeclampsia is determined by increased blood pressure accompanied 
by proteinuria. Pre-eclampsia complicates 3 to 8% of pregnancies and usually this disease 
is defined on the basis of new onset hypertension and albuminuruia developing after 20 
weeks of pregnancy.  Diagnostic blood pressure increases are either a systolic blood 
pressure of greater than or equal to 140 mmHg  or a diastolic blood pressure of greater 
than or equal to 90 mmHg. It is recommended that gestational blood pressure elevation 
be defined on the basis of at least two determinations. The repeat blood pressure should 
be performed in a manner that will reduce the likelihood of artefact and/or patient 
anxiety. (2) Absent from the diagnostic criteria is the former inclusion of an increment of 
30 mmHg systolic or 15 mmHg diastolic blood pressure, even when absolute values are 
below 140/90 mmHg.  This definition was excluded because the only available evidence 
shows that women in this group are not likely to suffer increased adverse outcomes (3) 
Notheless, women who have a rise of 30 mm Hg systolic or 15 mmHg diastolic blood 
pressure warrant  close observation, especially if proteinuria and hyperuricemia are also 
present. Proteinuria is defined as the urinary escretion of 0,3 g protein or greater in a 24 
hour specimen. This will usually correlate with 30 mg/dL or greater in a random urine 
determination. Because of the discrepancy between random protein determinations and 
24-hour urine protein in preclampsia, it is recommended that the diagnosis be based on 
24 hour urine specimen if at all possible, or if this is not feasible, it should be based on a 
timed collection corrected for creatinine excretion (2). Preeclampsia occurs as a spectrum 
but is arbitrarily divided into mild and severe forms. The terminology is useful for 
descriptive purposes.  
 8
The diagnosis of severe preeclampsia is confirmed when the following criteria are 
present:  
? Systolic blood pressure of 160 mmHg or greater, or diastolic pressure of 110 
mmHg or greater 
? Proteinuria of 2 g  or more in 24 hours (2 or 3 plus on qualitative examination) 
? Increased serum creatinine (greater than 1,2 mg/dL unless known to be previously 
elevated) 
? Persistent headache or cerebral or visual disturbances 
? Persistent epigastric pain 
? Platelet count less than 100,000/mm3 and/or evidence of microangiopathic 
haemolytic anemia (with increased lactic acid dehydrogenase) 
Eclampsia is the occurrence of seizures in a preeclamptic patient that cannot be 
attribuited to other causes. Edema occurs in too many normal pregnant women to be 
discriminant and has abandoned as a marker in preeclampsia by the National High Blood 
Pressure Education Program and by other classification schemes. 
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Preeclampsia superimposed on Chronic Hypertension 
Preeclampsia can occur in women who are already hypertensive and the prognosis for 
mother and fetus is much worse. Distinguishing superimposed preeclamspia from 
worsening chronic hypertension tests the skills of the clinicians. The suspicion of 
superimposed preclampsia mandates close observation with delivery indicated by the 
overall assessment of maternal-fetal health. The diagnosis of superimposed preclampsia 
is highly likely:  
1. In women with hypertension and no proteinuria early in pregnancy (prior to 20 
week’s gestation) and new-onset proteinuria, defined as the urinary excretion of 
0,3 g  protein or more in a 24h specimen 
2. In women with hypertension and proteinuria prior to 20 weeks’ gestation: 
- A sudden increase in proteinuria – urinary excretion of 0,3g protein or 
more in a 24-hour specimen or two dipstick-test result of 2+ (100mg/dl) with 
the values recorded at least 4 hour apart with no evidence of urinary tract 
infection 
- A sudden increase in blood pressure in a  woman whose blood pressure 
has previously benn well controlled 
- Thrombocytopenia (platelet count lower than 100000/mm3)  
- An increase in ALT or AST to abnormal levels 
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Gestational Hypertension 
The woman who has blood pressure elevation detected for the first time during 
pregnancy, without proteinuria is classified as having gestational hypertension. This non-
specific term includes women with preclampsia syndrome who have not yet manifested 
proteinuria as well as women who do not have the syndrome. The final differentation that 
the woman does not have preclampsia syndrome is made only post-partum. If 
preclampsia has not developed and blood pressure has returned to normal by 12 weeks 
post-partum the diagnosis of transient hypertension is made. If blood pressure elevation 
persists, the woman is diagnosed as having chronic hypertension. 
There are some problem with the classification; the degree of blood pressure elevation 
that constitutes gestational hypertension is controversial. Because average blood pressure 
in women 10-20 years is 120/60 mmHg, the standard definition of hypertension (blood 
pressure greater than 140/90 mmHg) is judged by some investigators to be too high. 
NHBPEP report that women with increased BP greater than 30 mmHg systolic or 25 
mmHg diastolic must be observed closely even if absolute blood pressure has not 
exceeded 140/90 mmHg. 
Preeclampsia has a clinical spectrum ranging from mild to severe forms and then 
potentially to eclampsia. Affected patients do not catch eclampsia or the severe forms of 
preclampsia but rather progress through this spectrum. In most cases, progression is slow 
and the disorder may never proceded beyond mild preclampsia. In other patients, the 
disease can progress more rapidly chancing from mild to severe over days to weeks. In 
the most serious cases, progression can be fulminant with mild preclampsia evolving to 
severe preclampsia or eclampsia over hours to days. 
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 HELLP syndrome 
In Hellp syndrome the acronym stands for Hemolysis, Elevated liver enzymes and Low 
platelets. This series of findings defines a reasonably consistent syndrome. Women with 
the Hellp tend to be older and are more likely Caucasian and multiparous. In many cases 
they are not hypertensive. (4) 
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Preclampsia: risk factors 
Preeclampsia is a common pregnancy disorder that originates in the placenta and causes 
variable maternal and fetal problems. The disorder is unique to pregnancy, characterized 
by poor perfusion of many vital organs  and completely reversible with the termination of 
pregnancy. Problems still arise owing the approaches in the management of PE; the 
successful management of PE requires an understanding of the pathophysiologic changes 
in this condition and the recognition that sign of preclampsia are only signs, not causal 
abnormalities. Preeclampsia occurs in about 4% of pregnancies. It would be useful to be 
able to identify the women at greater risk. As with all diseases there are no “typical” 
patients. Epidemiologic findings do indicate, that certain characteristics are more 
common in women who develop preclampsia. The most important is nulliparity. At least 
two thirds of cases occur in women during the first pregnancy. In some studies the PE 
was more common among women of lower socio-economic status, but other studies 
didn’t found established correlation. Eclampsia is clearly a disease of women of lower 
socioeconomics status; it is preventable by careful obstetric observation and prompt 
delivery. The lack of availability and use of good-quality obstetric care to indigent 
women is undoubtedly a mayor factor in the increased incidence of eclampsia. There is a 
relationship between the extremes of childbearing age and the onset of eclampsia. 
Because most pregnancies particularly the first occur in young women, most cases occur 
in this group. Some studies don’t found a correlation with the younger women and point 
the vision on older women. The incidence can vary in the different countries of the world; 
the relationship with the race is equally difficult to valuate. In the Collaborative Study the 
incidence of PE was higher in blacks. (5) This risk factor was observed especially in 
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nulliparous women (6) Analysis from a National Institutes of Health study of aspirin 
prophylaxis for low-risk pregnancies also failed to identify race as a risk factor (7). A 
characteristic of preclampsia-eclampsia is the tendency of the condition to occur in 
daughters and syster of women with a history of PE. The inheritance pattern was not best 
explained by simple mendelian inheritance. There is also a contribution of the fetal 
genome to preclampsia. Men who have fathered preeclamptic pregnancies are more likely 
to father preeclamptic pregnancies with new partners than the men who have never been 
fathers in preeclamptic pregnancies (8) In addition men born in preeclamptic pregnancies 
are more likely to be fathers in preeclamptic pregnancies than the who are born in 
nonpreeclamptic pregnancies. (9) Immunologic differences, features that compromise 
implantation and an increased sensitivity to respond to the systemic insult caused by 
reduced placental perfusion are factors presupposed for etiologic origin of PE. Some 
Human leukocyte antigen types are more common in the mothers and the fetus from 
preeclamptic pregnancies than others. Gene variants potentially leading to aberrations of 
endothelial function are more common in preeclamptic women. Mutations leading to 
increased risk factors for later-life cardiovascular disease, including function perturbing 
mutations of lipoprotein lipase genes and nethylene tetrahydrofolate reductase are 
associated with PE. (10-11) With all of these genetic polymorphism the result are 
inconsistent, being associated in some but not other populations supporting the 
heterogeneity of PE. Some medical disorder as diabetes also predispose to PE (50%). 
Preeclampsia is also more common in women with hypertension antedating pregnancy 
(20%). (12) Obesity is also risk factor. In the NIH study of aspirin for low-risk 
pregnancies, a dose relationship of obesity and PE was present. (5) The incidence of PE 
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increased with the magnitude of obesity. The mechanism of the increased risk could be 
related to increased insuline resistence, as PE is also more common in gestational 
diabetes (13). The relationship among obesity, insuline resistence and PE are part of an 
interesting relationship of PE to the metabolic or insulin resistance syndrome. This 
syndrome predispose to cardiovascular disease in later life and consist of obesity, 
hypertension, dyslipidemia (increased triglycerides and LDL cholesterol, decreased HDL 
cholesterol) and increased uric acid. All of these changes are present in women with PE. 
(14) Twin pregnancies also increase the risk of PE. In case of PE occurring before 24 th 
week’gestation, hydatidi-form mole should be suspected.  
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IUGR  
The most common definition of Intra uterine growth retardation is a fetus whose weight 
is below the tenth percentile for gestational age. This definition, however, is not 
universally accepted. Some authors may define it as a fetal weight below the fifth or third 
percentile.  Abdominal circumference (AC) below the tenth or fifth or third percentile 
and lack of normal growth of the AC on serial examinations are other definitions. Others 
may categorize growth disturbance based on absolute weight at birth, such as less than 
2500 or less than 1500g. However this obscures the distinction between smallness owing 
to prematurity and that owing to growth restriction. Causes and associations are Maternal, 
uterine placental, fetal, infection and teratogens. Once underlying fetal anomaly or 
aneuploidy is excluded, the most common associations are with maternal hypertension 
and a history of IUGR in previous pregnancy. Underlying uterine-placental dysfunction is 
a commonly evoked cause for otherwise unexplained fetal IUGR. Uterine placental 
dysfunction has been correlated with a range of pathologic findings, including smaller 
placentas, increase in the thickness of tertiary stem villi vessels wall and decrease in 
lumen circumference. Also confined placental mosaicism has been found to carry a 
higher risk of IUGR and adverse outcome including fetal death (15) Uterine placental 
dysfunction produces fetal hypoxia, which result in subnormal growth, oligohydramnios 
and alterations in blood flow. The strong association of growth restriction with still-birth 
support the need for early recognition of growth restriction. The primary means of 
detecting IUGR fetuses is demonstration of fetal weight to be less than the tenth 
percentile. The predictive value of true IUGR is further increased in association with 
oligohydramnios or abnormal Doppler studies. There are two forms of IUGR: the 
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symmetric and the asymmetric. Symmetric IUGR has been used to describe a growth 
pattern when all biometric measurements appear affected to same degree. The 
asymmetric IUGR has been used  to characterize a smaller AC compared to other growth 
parameters. Asymmetric IUGR would then show abnormal ratios such as HC/AC ratio or 
FC/AC ratio. (16) The term symmetric IUGR was suggested as more likely to reflect 
underlying fetal condition including aneuploidy. The term asymmetric IUGR reflected 
underlying uterine placental dysfunction. The IUGR condition is at higher risk for 
perinatal morbidity and mortality and the risk rising with the severity of the growth 
restriction. The diagnosis of IUGR is in part dependent on an accurate evaluation of 
gestational age. The incidence varies according to the population under examination, the 
geographic location, the standard growth curves used as reference and the percentile 
chose to indicate abnormal growth. Approximately one fourth to one third of all infants 
weighing less than 2500g at birth have sustained IUGR. Approximately 4-8% of all 
infants born in developed countries and 6-30% in developing countries are classified as 
growth restricted. (17) IUGR is usually associated with a small placenta; the its mean 
surface and the capillary surface area are reduced, implying a diminished diffusing 
capacity. Cytotrophoblastic hyperplasia, thickening of the basement membrane, placental 
infarction and chorionic villi are commonly present in placentas from pregnancies 
complicated by maternal vascular disease and IUGR. (18) More recently it has been 
reported that trophoblastic apoptosis is increased in IUGR, the mechanism being 
unknown. (19) The terminal villi are maldeveloped in IUGR pregnancies when and-
diastolic flow is demonstrated. Absent end-diastolic flow shows more occlusive lesions 
of the intraplacental vasculature than when end-diastolic flow is present. 
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 Vascular change in the placenta Site during pregnancy 
In normal pregnancy the spiral arteries increase greatly in diameter. Morphologically the 
endothelium is replaced by trophoblast and the internal elastic lamina and smooth muscle 
of the media are replaced by both trophoblast and an amorphous matrix containing fibrin. 
These changes occur originally in the decidual portion of the spiral arteries but extend 
into the myometrium as pregnancy advances and can even involve the distal portion of 
the uterine radial artery. The basal arteries are not affected. These morphologic changes 
are considered to be a vascular reaction to trophoblast, that results in increased perfusion 
of the placenta site. In placental site vessels of women with PE, the normal physiologic 
changes do not occur or are limited to the decidual portion of the vessels; myometrial 
segments of spiral arteries in myometrium retain the non pregnant component of intima 
and smooth muscle and the diameter of these arteries in about 40% that of vessels in 
normal pregnancy. In addition some spiral arterioles in deciduaand myometrium and 
some basal and radial arterioles are affected by a change termed acute atherosis. The 
affected vessels are necrotic and the usual components of the vessels wall are replaced by 
amorphous material and foam cells. This lesion is best seen in basal arteries because 
these arteries do not undergo the normal changes of pregnancy. It is also present in 
decidual and myometrial spiral arteries and can progress to vessels  obliteration. The 
obliterated vessels correspond to areas of placental infarction. Although some believe that 
this change occurs only in PE, others hold that it is present in placental site vessels in 
pregnancies with IUGR and without clinical evidence of PE. This findings indicates that 
PE is a disorder of placentation and that characteristic pathologic changes have preceded 
the clinical presentation of this disorder. The etiology of the decidual vascular lesion is 
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not known. The appearance of these vessels is somewhat similar to that of vessels in 
transplanted kidneys that have undergone rejection. This is suggestion of an immunologic 
etiology. 
 
The placenta is a unique organ with dual blood circulation functioning throughout fetal 
development. The architecture and functions of the placenta, where maternal blood flows 
in the intervillous space, present haemostatic problems, mainly the risk of haemorrhage. 
Placental throphoblasts express and produce coagulation components, partecipating not 
only in haemostatsis, but also in the placental vascular development and differentiation. 
The expression of tissue factor (TF), membrane phosphatidylserine and fibrin render the 
throphoblasts pro-coagulan, thus compromising the risk of bleeding while exposing the 
placenta to pro-thrombotic risks. Local inhibitory mechanism TFPI-1 and TFPI-2, 
thrombomodulin, annexin V and the fibrinolytic system-limit coagulation activation and 
fibrin deposition. Pregnancy complications have been associated with abnormalities in 
the functions of these inhibitors. Haemostatic processes in placental cells change 
throughout gestation and are affected by the changing requirements of the organs. 
Although most systemic coagulation proteins are produced by the liver, regulation of 
haemostasis is achieved by cellular membrane components or by locally expressed or 
secreted proteins. TF , the main activator of coagulation, is a glycoprotein produced and 
induced in monocytes and endothelial cells (EC), fibroblasts and macrophages. A 
comprehensive study by Faulk et al  (20) used two types of specific antibodies for TF in 
an immunoistological study which localized TF in placental mcrophages , EC or 
fibroblasts-like cells, but not in throphoblasts. A study by Lakasing et al (21) supported 
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this findings by localizing TF in perivascular cells in the placenta. However, other studies 
have demonstrated that placenta throphoblasts are able to synthesize and express TF. 
Increased levels of TF were demonstrated by activity assays and reactivity by western-
blot in STB membranes isolated from villi (22-23). It has been demonstrated the presence 
of large amounts of ready-to-use TF in the placenta (24) . Teleologically, this seems to be 
essential for the maintenance of haemostasis in the placenta. The inhibitor of the TF 
activation pathway is TFPI; TFPI is produced and secreted by endothelial cells, 
potentially by microvascular EC (25). TFPI mRNA is highly expressed in placenta, 
mostly in megakaryocytes and endothelium of small vessels and macrophages in the villi 
of term placenta (26). During placental development, TFPI is expressed in STB and 
vascular endothelium from 10 weeks to term. The relative expression of TFPI mRNA 
was studied in several organs (23) and compared to other endothelium specific proteins: 
thrombomodulin (TM), von Willebrand factor (vWF), anf TF. TFPI in placenta was 
found to be most abundant among the examined organs, while the level of vWF and TM 
were relatively low. Sprecher et al (27) have cloned the gene from the placenta and 
defined it as TFPI-2, which is homologous to TFPI/lipoprotein associated coagulation 
inhibitor. Although TFPI-2 has similarity in the domain structure and partial homology to 
TFPI, its inhibitory spectrum for serine protease is reported to be different from that of 
TFPI. TFPI-2 is a poor inhibitor of TF/VIIa complex, as compared to TFPI, but it is  a 
strong inhibitor of factor Xa, plasmin and trypsin. TFPI-2 is found in the maternal serum 
of normal pregnancies , its serum level is increased with pregnancy progress, and it is 
relatively high in the sera of patients with trophoblastic disease. It was demonstrated that 
TFPI-2 is also expressed in human tissues, such as liver, skeletal muscle, heart, kidney 
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and pancreas (28). It can be speculated that potency of blood vessels is maintained 
through TFPI blocking of the endothelial initiated coagulation, while TFPI-2 having 
different affinities for coagulation complexes- may play a similar function in placental 
STB to protect blood flow in the villous spaces from hypercoagulation. Fibrinolysis is 
activated by plasminogen activators ( PA) t-PA and urokinase (U-PA) and is inibited by 
plasminogen activator inhibitor type 1 (PAI-1) or type 2. Both activators and inhibitors 
are secreted by vessel cells following stimulation by cytokines and growth factors (29). 
Two distinct fast acting inhibitors of PA have been identified. immunological analysis 
have shown that PAI-1 and PAI-2 are present in normal human placenta tissue (30) and 
that plasma levels of both inhibitors increase during the course of pregnancy (31) . PAI-1, 
the phisiological inhibitors of both urokinase and t-PA, is syntetized mainly by 
endothelial cells, and is a primary regulator of the fibrinolytic system in vivo. 
Overexpression of PAI-1 may compromise normal fibrin clearance mechanism and 
promote pathological fibrin deposition, when the clotting cascade is activated. The 
presence of PAI-1 and expression of mRNA have been studied in normal and 
pathological pregnancies (29, 31). Plasma and placental PAI-1 levels were significantly 
elevated in pregnant women with severe PE. PAI-2, initially isolated from human 
placenta (32), is produced mainly by macrophgages and cheratinocytes, but vidence 
points to its presence and possible role in placental cell invasion in the uterus (33). 
Estelles et al (29) claimed that elevated plasma levels of PAI-1, but not PAI-2, have been 
implicated in mediating fibrin deposition and occlusive lesions, that occur within the 
placenta vasculature of villous tissue obtained from PE and IUGR. Limited information is 
avilable on factors regulating production of PAI-1 within either normal or PE/IUGR 
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placenta. A variety of factors, such as cytokines, growth factors and changed blood flow, 
are capable of affecting the expression of PAI-1, as well as that of TF. Kanfer et al have 
measured procoagulant and anticoagulant fibrinolytic and antifibrinolytic ( TF, TM, t-PA 
urokinase, PAI-1 and PAI-2) activities in placenta extracts as well as the amount of 
fibrinoid deposition in term healthy placentas and in placentas from hypertensive PE 
women. ( 34 ). It was demonstrated that the hypertensive group had a higher placental 
content of PAI-2 and contained fibrinoid material. The increased documented change in 
PAI-2 could explain the imbalance of local fibrinolytic system in gestational 
complications. The presence of a normal placental vasculature is a fundamental feature of 
fetal development.  
It is known that inherited ( protein C, protein S, antithrombin deficiencies) or acquired 
(antiphospholipid antibodies) causes of thrombophilia can be associated with obstetric 
complications as early and late fetal losses. (35; 36). The thromboxane A2 (TXA2) has a 
pivotal role in the obstetric pathology, because is a powerful proaggregatory and smooth 
muscle cell connstrictor agent (37) In some different districts two isoforms of its receptor 
(TP) are expressed, which have an antithetic function.TXA2 is platelet agonist, smooth 
muscle cell constrictor, and mitogen. Urinary TX metabolites (TX-M) excretion is 
increased in syndromes of platelet activation and early in both normal pregnancy and in 
pregnancy-induced hypertension. (38) A further increment occurs in patients presenting 
with severe preeclampsia, in whom TX-M correlates with other indices of disese severity. 
(37) TXA2 exerts its effects through a membrane receptor (TP, of which two isoforms 
(alpha and beta) have been cloned. Overexpression of TP in the vasculature under the 
control of pre-proendothelin-1 promoter (38) results in a murine model of intrauterine-
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growth restriction (IUGR), which is rescued by timed suppression of TX synthesis with 
indomethacin. IUGR is commonly associated with maternal diabetes, maternal diabetes, 
or cigarette smoking, 
conditions associated with increased TXA2 biosynthesis. (37, 38, 39) Recently, in a 
murine model it has been demonstrated that the overexpression of the TP (genotype 
TP++) is associated to a phenotype very similar to that of the human IUGR.Embryos 
from TP++ females were consistently smaller in size and body weight compared to 
embryos from wild type females. Moreover, gross examination showed that the placentas 
of the TP++ females were smaller than those of wild-type mice, but no thromboses were 
observed. Moreover, it is known that the overexpression of human TP in mice causes a 
phenotype very similar to that of human IUGR. (38). 
During the last years, a great interest has been given to the haematological causes of 
recurrent miscarriage and of complicated pregnancy. It is well known that women 
affected by congenital or acquired thrombophilic alterations have a significant increase in 
miscarriage and complicated pregnancy rate (35).  
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DOPPLER and Pregnancy 
 
 
Doppler studies are generally used to screen for IUGR or PE, with the possible exception 
of uterine artery Doppler. Rather, Doppler studies provide greater specificity after 
identifying a fetus with a suspected IUGR or fetal compromise. Although techniques 
such as Doppler velocimetry have improved the assessment of High risk fetuses, the 
challenge that has not been adequately addressed is how to identify those pregnancies 
that need to be referred for investigation and closer surveillance. 
Blood flow in arterial vessels, mainly the umbilical artery, the middle cerebral artery 
(MCA) and the foetal thoracic descending aorta, can be assessed using various indices. 
These indices include the systolic (S) to diastolic (D) ratio, pulsatility index (PI) (PI= S-
D/Vm, where Vm  is the mean of maximal velocities throughout the cardiac cycle) or 
resistive index (RI) (RI= S-D/S). 
The PI has the advantage of values even when the diastolic flow component is absent. 
Impedance to flow into the ductus venous or into inferior vena cava can also be measured 
by calculating PI, referred to as PI for veins.  
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PULSATILITY INDEX = A-B/ Mean 
 
POURCELOT RATIO = A-B/ A 
 
SYSTOLIC/DIASTOLIC RATIO = A/B 
 
Fig. 1: Illustration of commonly used indices of Doppler waveform 
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Uterine artery Doppler  
 
Doppler US provides a non-invasive method for the study of the uteroplacental 
circulation. In normal pregnancy, impedance to flow in the uterine arteries decrease with 
gestation, which may be the consequence of trophoblastic invasion of the spiral arteries 
and their conversion into low-resistance vessels. PE and IUGR are associated with failure 
of trophoblastic invasion of spiral arteries and Doppler has then shown that impedance to 
flow in the uterine arteries is increased. Doppler sampling can be performed at the level  
of the main uterine arteries at the level of the arcuate arteries (1)or as a combined or as a 
combined approach of both sampling sites (2). Color Doppler visualization of the uterine 
arteries at the crossover with the external iliac artery is now the sampling site of choice. 
The normal waveform pattern shows a low resistance, high flow pattern throughout 
diastole (Fig. 2-3). The abnormal waveform patterns show high resistance and 
protodiastolic notch (Fig. 4-5).  
Gestational age (GA) at sampling is usually 16-20 weeks and 22-24 weeks in a one-stage 
or two stage screening. High impedance to flow is generally assessed by RI or PI with 
cutoff values of 0,58-0,63 and 1,85, respectively, at these GA. Early diastolic notch when 
bilateral is another and more stringent way of describing abnormal results. Notch 
quantification has not proven to be useful. A series of screening studies involving 
assessment of impedance to flow in the uterine arteries have examined the potential value 
of Doppler in identifying pregnancies at risk of PE or other complication of impaired 
placentation. The results of an analysis of 15 studies (3) show that increased impedance 
to flow in the uterine arteries is associated with an increased risk of developing PE, 
IUGR, and perinatal death. In addition, women with normal impedance to flow in the 
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uterine arteries constitute a group at low risk of developing such impaired placentation 
related complications. Increased impedance to flow identified approximately 50% of 
pregnancies that will develop PE and around 30% of those that will develop IUGR 
subsequently. Abnormal Doppler is better at predicting severe rather than mild disease. 
The sensitivity for severe disease requiring premature delivery was approximately 80% 
for PE and 60% for IUGR. In the pooled data from all studies, the likelihood ratio for the 
subsequent delivery of a growth-restricted infant, occurrence of PE and perinatal death in 
women with an abnormal result was 3,7 5 and 2,4 respectively and the likelihood ratio 
was 0,7, 0,5 and 0,8 respectively for women with normal Doppler results. The incidence 
of complications varied from 2% to 24%; predictive values increased with the prevalence 
and the false positive rates decreased with gestation. Bilateral notches are found in 20-
30% of pregnancies at 12 weeks, through to 10-20% at 16 weeks, around 10% at 20-22 
weeks and less than 5% at 23-24 weeks of gestation. (4). 
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Fig. 2 Uterine left artery morphology, velocity waves and RI value were regular. 
The normal waveform pattern shows a low resistance, high flow pattern throughout 
diastole. Blood flow in left uterine artery in normal fetus. 
 
 
 
Fig. 3 Uterine right artery morphology, velocity waves and RI value were regular. 
The normal waveform pattern shows a low resistance, high flow pattern throughout 
diastole. Blood flow in left uterine artery in normal fetus. 
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Fig. 4 Uterine left artery morphology, velocity waves and RI value were irregular. 
There is protodiastolic incisure. The abnormal waveform pattern show high 
resistance and protodiastolic notch. Blood flow in left uterine artery in fetus with 
intrauterine growth retardation (IUGR). 
 
 
 
Fig. 5 Uterine right artery morphology, velocity waves and RI value were irregular. 
There is protodiastolic incisure. The abnormal waveform pattern show high 
resistance and protodiastolic notch. Blood flow in right uterine artery in fetus with 
intrauterine growth retardation (IUGR). 
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Umbilical artery Doppler 
 
Decreased resistance to flow in the umbilical artery is normally seen between the fetal 
bladder and the placenta cord insertion and due to the reservoir effect of the placenta on 
impedance to flow along the umbilical cord. This will, however, remain within normal 
limits in normoxemic fetuses with normal placental resistance. (Fig. 6) The flow in the 
umbilical artery is a reflection of the placenta resistance mainly and, to a certain extent, 
of the fetal systemic resistance. However, when the diastolic component is reduced or 
absent (Fig. 7-8) or mainly reversed (Fig. 9) fetal cardiac decompensation is possible.  
Metanalyses suggest a 35-40% decrease in perinatal mortality when considering one 
umbilical Doppler measurement in high risk fetuses (5). This impressive effect of 
umbilical artery Doppler is mainly due to the high positive predictive value of 
absent/reversed and diastolic flow on perinatl mortality. (6) Absence and especially 
reversal of end diastolic flow of the umbilical artery Doppler is a worrisome finding 
associated with increased risk of perinatal and neonatal death as well as other 
complications. Elevation of umbilical artery Doppler resistance with diastolic flow is less 
predictive. 
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Fig. 6 Blood flow in umbilical artery (UA) in normal fetus. Umbilical artery 
morphology, velocity waves and PI value were regular. 
 
 
 
 
 
 
Fig. 7 Blood flow in umbilical artery (UA): the diastolic component is reduced. 
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Fig. 8 Blood flow in umbilical artery (UA): the diastolic component is absent. 
 
 
 
 
 
Fig. 9 The diastolic component is reversed. Umbilical artery morphology, velocity 
waves and PI value were irregular. There is reversal of end-diastolic flow in the 
umbilical artery (ARED flow). 
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Middle cerebral artery Doppler 
 
The sampling site of Middle cerebral artery (MCA) Doppler is along the sphenoid wing 
at the internal third of the vessels. This vessel often presents with an ideal angle of 
insonation. Special attention must not press on the transducer, which could result in a 
significant decrease in diastolic flow in the MCA (7). PI in the MCA decrease with the 
gestation (8) Doppler easily shows vascular redistribution. This redistribution includes a 
decrease in resistance to flow in the MCA together with an increase in the resistance to 
flow in the fetal thoracic aorta. The resistance pattern of the middle cerebral artery 
Doppler should always be greater than the umbilical artery Doppler resistance before 
birth. (Fig.10) In the setting of fetal hypoxia, blood is preferentially shunted to the brain 
as the “brain sparing” adaptive response (Fig. 11). A middle cerebral artery Doppler 
waveform showing less resistance (lower S/D ratio PI or RI) than the umbilical artery 
Doppler is the reverse of the normal relationship and is diagnostic of the brain sparing 
effect. Sterne et al (9) found that this redistribution is associated with low birth weight 
and academia, and the severity of the abnormal Doppler pattern correlated with a shorter 
interval to delivery and the need for emergency delivery. The middle cerebral artery 
Doppler may be more sensitive than umbilical artery Doppler for identifying fetuses at 
risk. SGA fetuses with normal umbilical artery Doppler but abnormal uterine and MCA 
have an increased risk of developing distress and being delivered by emergency 
caesarean section. Furthermore, abnormal velocimetry of the uterine and MCA was 
independently correlated with the risk (10).   
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Fig. 10 Middle cerebral artery (MCA). The resistence pattern of the middle cerebral 
artery Doppler should always be greater than the umbilical artery Doppler 
resistance before birth. 
 
 
 
Fig. 11. A middle cerebral artery Doppler with the “brain sparing” adaptive 
response. The waveform showing less resistance (lower S/D ratio PI or RI) than the 
umbilical artery. 
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Venous Doppler 
 
Doppler examination of the fetal veins is feasible and concerns mainly the ductus 
venosus and the inferior vena cava. Tha advantage of ductus venosus (DV) (Flow pattern 
Fig. 12) over the inferior vena cava in the assessment of IUGR fetuses is that the wave in 
the ductus venosus gets reversed only in severely compromised fetuses, thus acting as a 
sign of fetal demise. The DV can be identified with color flow imaging and duplex 
doppler (Fig. 13) 
Imaging is performed either in sagittal or an oblique section of the fetal abdomen to 
visualize the communication between the umbilical vein (portal sinus) and the inferior 
vena cava. Presence of characteristic high velocity signal in the color-doppler mode 
ensures identification. Recording is taken in the inlet of the DV with an insonation angle 
as near to the long axis of the vessels as possible (11). Blood flow patterns may reflect 
change in pressure between the vessels and the right atrium throughout the cardiac cycle. 
Velocities are maximal during ventricular systole (S wave) in relation with a rapid filling 
of the atria; the second peak (D wave) corresponds to early ventricular diastole and flow 
velocity is minimal during atrial contraction (A wave). As with fetal arteries, various 
indices can be used to describe the waveform patterns of the DV. These indices include 
S/A ratio, the peak velocity index for veins (PVIV= A-A/D) and PIV (PIV= S-A/ time 
averaged maximum velocity). 
Various pathologic situations can influence the normal flow pattern (fig 14): 
- a decrease in myocardial contractility, which can be seen in hearth 
compression by pericardial or pleural effusion but also in subendocardial 
ischemia in severely acidotic fetuses; 
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- an increase in cardiav afetrload which can be seen with high placental 
resistance or in pulmonary stenosis with intact septum; 
- an increase in cardiac preload, which impairs complete auricular emptying 
seen in hypervolemia in a recipient in twin-to-twin transfusion syndrome 
and other situations which increased cardiac output. 
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Fig 12. Ductus venosus flow patterns. A: Normal waveform pattern. Normal systole 
consist of two peaks, with the first corresponding to ventricular systole (S) and the 
second to ventricular diastole (D). reduced velocity is observed during atrial diastole 
(A) but flow is always continuos above the baseline. B: Abnormal waveform pattern 
with reversal of A wave. 
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Fig. 13 Ductus venosus flow patterns. A: Normal waveform pattern. Normal systole 
consist of two peaks, with the first corresponding to ventricular systole (S) and the 
second to ventricular diastole (D). Reduced velocity is observed during atrial 
diastole (A) but flow is always continuos above the baseline. 
 
 
 
 
Fig. 14 Abnormal waveform pattern with reversal A wave. 
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OBJECTIVES OF THE STUDY 
 
In the first part of the study, we will enroll the number of patients expected to accomplish 
the aims of the study. We will select at least 15-30 pregnancies complicated for the 
presence of pre-eclampsia (the occurrence of gestational hypertension with significant 
proteinuria) and severe fetal growth restriction (FGR).During pregnancy women will 
undergo serial Doppler examination of the uterine and umbilical arteries. Women will 
undergo routine evaluation of uterine arteries and umbilical artery (UA). Color Doppler 
examination of target vessels will be performed according to Bilardo ( Am J Obstet 
Gynecol 1990; 162: 115-20) and Albaiges ( Obstet Gynecol 2000; 96: 559-64). Doppler 
measurements will be taken from the frozen image after at least five consecutive uniform 
flow velocity waveforms during period of fetal rest and apnea. Abnormal UA Doppler 
flow velocimetry will be defined as a pulsatility index (PI) >2 standard deviations (SD) 
above the mean for gestational age by local reference values and/or absence or reversal of 
end-diastolic velociteis. Fetuses with abnormal UA Doppler PI will be longitudinally 
evaluated by serial fetal Doppler examination of ductus venosus (DV) flow velocimetry, 
by non-stress test and biophysical profile score. Uterine artery flow velocimetry will be 
considered abnormal in cases of bilateral uterine artery notches or when the mean PI of 
the two vessels will be>95th  centile of the reference range for gestational age in our study 
population. For DV, an elevation of the peak velocity index >2SD above the gestational 
mean age will be considered abnormal. The time interval between Doppler examinations 
will depend on Doppler investigation results. In case of UA absent or revers end-diastolic 
flow, fetal monitoring will be performed daily. Moreover, fetal growth will be monitored. 
We will pay particular attention to select placentas from pregnancies with newborns 
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showing  a percentile below 3th or 5th  centile. Using this cut-off, a more severe setting 
will be enrolled and it is conceivable that a greater effect on the gene expression of 
variables investigated will be identified.  
During the first phase of the study we will investigate whether different areas of placenta 
express different amounts of the same marker in order to obtain information about 
homogeneity of expression.  
During the second phase of the study, we will evaluate the expression of markers 
considered in pathological placentas as compared to normal ones. In particular, our Unit 
will obtain slices from all collected placentas, then we will obtain homogenate from each 
section. Finally, we will extract total RNA and synthesise cDNA determining the 
expression of each marker in all cDNA samples obtained. 
During the second phase of the present application, all schedulad laboratory variables 
will be determined in all patients enrolled. We will obtain specific complementary DNAs 
from placentas of women with complicated pregnancies. Then we will investigate allele 
and genotype frequencies of common gene variations. In parallel, in placenta obtaind in 
women presenting with a complicated pregnancy, the modulation of the gene expression 
of a series of factors of the coagulation/fibrinolytic pathway will be investigated.  
We will isolated total RNA by placentas after homogeneization with 1 ml Trizol® 
reagent (Invitrogen) according to the manufacturer's instructions. Phenol-phase 
separation will be performed with gel-phase tubes (Eppendorf, Hamburg, Germany) in 
order to prevent protein contamination of the RNA. RNA will be dissolved in 20 ul 
RNase-free H2O and exposed to 55 °C for 5 min to increase solubility. The RNA 
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concentration will be determined at 260 nm with a plate-reading spectrophotometer 
(SPECTRAmaxTM; Molecular Devices, Wokingham, UK). 
Then, specific cDNAs will be synthesed. Briefly, a mixture of 0.5 ug total RNA and 0.25 
ug Oligo dT (Invitrogen) per sample will be subjected to 65 °C for 5 min to promote 
primer annealing. A volume of 8 ul RT master mix containing 1¥ RT buffer, 25 mM dTT, 
1.25 mM dNTP and 200 U moloney murine leukemia virus reverse transcriptase will be 
added, and the mixture incubated at 37 °C for 70 min. The RT reaction will be terminated 
at 95 °C for 5 min, whereupon samples will be frozen to -20 °C. 
Genomic DNA will be extracted from all probands enrolled. DNA will be extracted from 
white blood cells using the salting-out method. All gene variants will be investigated by 
using PCR and restriction enzymes. Primer will be "ad hoc"; designed and synthetized. 
Random DNA manual or authomated sequencies will be made to verify results obtained 
during the routine screening of genetic polymorphisms investigated. An independent and 
blinded control of clinical evaluation of patients, including all information obtained, and 
of laboratory data will be done by investigators who participate to the present project. 
PCRs will be carried out in 50 microl samples, using a Perkin Elmer-Cetus termal cycler 
(Perkin-Elmer, Norwalk, CN), containing n0,1 microg of genomic DNA, 10 pmoli of 
each primer, 125 microM of dNTP, 5 mM ofi Tris HCl pH 8.3, 50 mM of KCl, 2.5 mM 
of MgCl2, 0.01% (peso/volume) of gelatin, and 1 U of Taq polimerase. The solution will 
be overlaid with 50 microl of mineral oil and after a denaturation at 95 °C for 3 min, will 
undergo 30 cycles of amplification, 1 min at 95 °C, 1 min at 56-60 °C, and 2 min at 72 
°C. Then, 5 microl of the amplification product will undergo agarose gel electrophoresis 
in TAE buffer (40 mM TRIS-Acetato, 1 mM EDTA pH 7.7) conteining 0.5microg/ml of 
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ethidium bromide, and visualized under UV. Genotyping analyses will be carried out 
according to standard procedures. Random DNA manual or authomated sequencies will 
be made to verify results obtained during the routine screening of genetic polymorphisms 
investigated. An independent and blinded control of clinical evaluation of patients, 
including all information obtained, and of laboratory data will be done by investigators 
who participate to the present project. SNPs data will be confirmed by direct fluorescent 
dye-terminator cycle sequencing of PCR products and subsequent analysis on capillary-
based autosequencers (models ABI-3100 and ABI-310, Applied Biosystems). 
From placenta sampled by other Units partecipating into the current study and stored at -
80°C, RNA will be purified using standard methods e cDNA will be obtained. Finally, 
the material will be tested using the quantitative PCR tecnology for the placental 
expression profile of a series of genes, i.e. tromboxane A2 receptor, PAI-2, tissue factor, 
TFPI, etc. Constitutive expressed genes, such as beta-actin and GAPDH will serve as 
standard for the normalization of the results. 
The above-mentioned activity will be also performed for other Centers that collaborate to 
the investigation. Each transcript will be studied taking advantage on specific probes. 
Briefly, total RNA will be isolated from tissue using the Trizol reagent (Invitrogen) 
according to the manufacturer's instructions. Phenol-phase separation will be performed 
with gel-phase tube (Eppendendorf) in order to prevent protein contamination of the 
RNA. Then, RNA will be dissolved in 20microlters RNase-free water and exposed to 55 
°C for 5 minues to increase solubility. The RNA concentration will be detrmined at 
260nm with a plate-reading spectrophotometer. For the cDNA synthesis , amixture of 0.5 
micrograms of total RNA and 0.25 micrograms Oligo dT (Invitrogen) per sample will be 
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subjected to 65°C for 5 min to promote primer annealing. A volume of 20 microliters of 
Rt reaction containing 8 microliters of RT master mix containing 1X RT buffer, 25 mM 
dTT, 1.25 mM dNTP and 200 U of moloney murine leukimia virus reverse transcriptase 
will be incubated at 37°C for 70 min. The probes that will be used for quantification of 
targets and endogeneous controls will be designed according to the TaqMan technology 
(Applied Biosistems) using the Primer Express (Applied Biosystems) computer 
software. The real-time PCR will be performed on the ABI prism 7700 (Applied 
Biosystems) PCr and detection instruments. The fluorescent signal from the dye 6-
carboxyfluorescein (6-FAM) at the 5' end of the probe will be quenched by another 
fluorochrome, TAMRA, at the 3' end. The quenching effect will terminate as the probe is 
cleaved due to the 5' exonuclease activity of the amplitaq Gold (Applied Biosystems) 
enzyme and a fluorescent signal emitted. The emittance will be proportional to the 
amount of amplified product, until it reaches the lag phase of the PCR. A threshold value 
setted above the baseline will reflecte by the average change of emittance during the first 
PCR cycles. The CT value (cycle number), is the point at which the emittance passes 
above the baseline and thus mirrors the accumulation of PCR product in a specific well of 
the PCR reaction. The real-time PCR reactions will be performed on plates using 
adhesive seals as covers. A master mix will be prepared for each plate and each 
quantitation target in 25 microliters reactions, with final concentrations of 1x Buffer A, 3 
mM MgCl2, 0.2 mM dNTP, 200 nM probe and primers and 1.25 U Amplitaq Gold. The 
PCR will be programmed as follows: initial denaturation at 95 °C 10 min followed 40 
cycles of 95°C for 20 sec and 58-60°C for 20 sec . Gene polymorphism of hemostatic 
factors will be studied assessing factor V Leiden, G20210A prothrombin, C677T 
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methylenetetrahydrofolate reductase (MTHFR), plasminogen activator inhibitor 4G/5G, 
and platelet glycoprotein PL A1A2 gene mutations, and dosing hcy, proteins C, S, free S, 
antithrombin III, anticardiolipin antibodies IgG and IgM, dilute Russel's viper venom 
time, activated partial thromboplastin time, Factor VIII, Factor XI, lipoprotein (Lp)(a), 
and plasminogen activator inhibitor activity (PAI-Fx). During the course of the second 
phase of the present application, the accomplishment of all laboratory evaluations 
scheduled will provide a complete output of variables investigated in different settings of 
patients and in the related groups of controls. This constitutes one of the major goal of the 
present application: the setting up of an archive that will include all clinical information 
obtained and DNA samples. This archive may be of help for further clinical studies 
addressing this issue and looking for new strategies for the prevention, diagnosis, and 
therapy of some complicated pregnancies. During the third phase of the present 
application, the statistical analysis of all data obtained will be carried out looking for 
significant associations. 
All the statistical analyses will be performed according to the Statistical Package for 
Social Science (SSPS 10.0 for PC). The significance of any difference in means will be 
evaluated by non-parametric test, whereas the significance of any difference in 
proportions was tested by chi-square statistics. The allele frequencies were estimated by 
gene counting, and genotypes were scored. The observed numbers of different genotypes 
will be compared with those expected for a population in Hardy-Weinberg equilibrium 
using a chi-square test. The significance of the difference of observed alleles and 
genotypes between the groups will be tested using the chi-square analysis also after 
grouping homozygous and heterozygous carriers of each allele, investigating in addition 
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to a codominant model the possibility of a relationship assuming a dominant or recessive 
model. Statistical significance was taken as p<0.05. The statistical analysis will calculate 
exposure Odds Ratios (ORs) and 95%-confidence intervals (CI) as estimates of the 
relative risk associated with specific risk factors: i. e., gene variants, environmental 
factors, and their combination. ORs will be calculated by cross-tabulation and 
unconditional logistic regression. Statistical uncertainty will be take into account by the 
construction of confidence intervals based on a Poisson distribution of the number of 
events, i. e., by the method of Woolf or according to the standard error derived from the 
maximum likelihood estimator of the model. Since incident cases and population 
controls are included, the ORs represent measures of the incidence rate ratio. Adjustment 
for putative confounders will be performed by multivariate modelling. 
The joint effect of risk factors, either both genetic (gene-gene interaction) or genetic and 
acquired (gene-environment interaction) will be assessed. Basically, risk estimates will 
derived for main effects and joint effects. Interaction will be defined as the risk for the 
joint presence exceeding the sum of the separate effects (testing for departure from 
additivity). This will be done by logistic regression, with multiplicative-additive models. 
The sample size will be sufficient to detect moderate departures from additivity for 
genetic variants which are still not multiplicative, and to detect small departures from 
additivity for the gene-environmental combination of risk factors - since these are more 
common. During the course of the third phase of the present application, it is planned to 
get results of the statistical analysis. All information obtained will serve to better define 
the clinical and genetic profile of clinical settings enrolled. 
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During the fourth phase of the present application, information deriving from the 
statistical analysis will be evaluated. Results obtained will be matched with data from 
clinical studies of the literature. At the end, all data obtained will serve as starting point to 
set up new strategies for the primary and secondary prevention of pregnancy 
complication investigated. During the course of the fourth phase of the present 
application, it is planned to set up new strategies for the primary and/or secondary 
prevention of pregnancy complication investigated. 
One of the most important intermediate results will be the accomplishment of a sample 
size comparable to that scheduled in the aims of the present applications. All clinical and 
laboratory information obtained will provide an illustration of patients and controls 
enrolled. We suggest that the final step of the project would be positively completed 
whether we will obtain the accomplishment of the statistical analysis of all data obtained 
in the entire group of women enlisted. This information will be presented in national and 
international meetings and will be submitted as original manuscripts to peer-reviewed 
international journals, quoted in Index Medicus. From a scientific point of view, the 
communication of results obtained in the course of the present application will allow to 
verify the meaning and the weight of our thoughts and conclusions of the study. 
Moreover, at the end of the study it will be possible to contact other Researchers in the 
field who, in addition to critically discuss conclusions obtained, will be able to verify in 
different and independent clinical settings of patients and controls the validity of clinical 
protocols of screening and prevention provided by the present application. 
We expect that the present study will provide results that will allow us: (1) to set up new 
protocols for the primary identification of at risk subjects; (2) to arrange new therapies on 
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the basis of the knowledges derived from this kind of study; (3) to identify a genetic risk 
profile that will account of interactions with environmental, acquired, and inherited risk 
factors; (4) to set up an archive that will include all clinical information obtained and 
DNA samples. This archive may be of help for further clinical studies addressing this 
issue and looking for new strategies for the prevention, diagnosis, and therapy of 
complicated pregnancies. If we will be able to attain prefixed aims, in addition to the 
improvement of our knowledge about the physiopathology, we will obtain to the woman, 
his family, and the whole community, a significant reduction of social and economic 
problems deriving from the occurrence of unsuccessful pregnancies. 
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To investigate whether different areas of placenta express different amounts of the same 
marker in order to obtain information about homogeneity of expression we start our study 
presenting data obtained from placentas of women with successful pregnancy outcome. 
 
App. 1 
 
Few studies have been carried out to investigate whether different areas of at term 
placenta express different amounts of markers involved in the placental haemostasis and 
angiogenesis. We evaluate correlation between factors involved in the local haemostasis 
and angiogenesis in term human placenta. 
 
App. 2  
 
After we investigate placenta expression profile of different coagulation markers in 
human placentas from complicated pregnancies. 
App. 3 
App.4 
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App. 1 
 
EXPRESSION PROFILE OF DIFFERENT COAGULATION 
MARKERS IN HUMAN PLACENTAS FROM UNEVENTFUL 
PREGNANCIES 
 
 
INTRODUCTION 
The architecture and functions of the placenta present haemostatic problems, mainly the 
risk of haemorrhage. Placental throphoblasts express and produce coagulation 
components, partecipating not only in hemostatis, but also in placental vascular 
development and differentiation. The expression of tissue factor (TF), membrane 
phosphatiylserine and fibrin render the throphoblasts pro-coagulant, thus compromising 
the risk of bleeding while exposing the placenta to pro-thrombotic risk. Local inhibitory 
mechanisms act via TFPI and TFPI-2, thrombomodulin, annexina V. Pregnancy 
complications have been associated with abnormalities in the functions of these 
inhibitors. Moreover, different isoforms of the thromboxane A2 receptor seem to be 
differently expressed in mice with fetal growth restricted fetuses. The aim of our study 
was to investigate whether different areas of placenta express different amounts of the 
same marker in order to obtain information about homogeneity of expression. 
 
METHODS 
Here we present data obtained from 4 placentas of women with successful pregnancy 
outcome. The placentas were dissected starting from the inserction of umbilical cord 
towards the peripheral zone. From each section RNA was extracted by means Invitrogen 
Trizol, Reagent. Then cDNA was obtained by means RT-PCR (Promega Reverse 
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trascription system), and the expression of TF, TFPI, TFPI-2, PAI-2, and thromboxane 
receptor α-isoform and β-isoform was evaluated in different areas of placenta by means 
of APPLERA ABI PRISM 7700. Data were expressed as percent of GAPDH for each 
sample analyzed.  
 
RESULT 
No significant difference (p>0,05) between central and peripheral areas of placentas was 
observed for all markers analysed. Data are shown in the Table.  
 
CONCLUSION 
The aim of our study was to investigate whether different areas of placenta express 
different amounts of the same marker in order to obtain information about homogeneity 
of expression. These preliminary data will be useful for comparing the expression of 
these markers in normal placentas with that of placentas from complicated pregnancies 
(preeclampsia, IUGR)  
 
    
 
 TF%   TFPI%   
TFPI-
2%  PAI-2  
TXA2R 
α  
TXA2R 
β  
  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
N 105 8,2 112,5 5,8 135 15,1 92 5,8 81 3,7 75 3,1 
A 105,3 25,6 114 2,6 136 4,7 93 1,8 86,4 4,4 76 3,6 
B 105,6 4,2 112,5 2,9 134 7,6 94,5 3,1 83,3 4 79 2,6 
 
TABLE .1 Legend N: zone corresponding to the inserction of umbilical cord; A: zone next to N, B: 
marginal zone of placenta. 
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App.2 
Correlation between factors involved in the local haemostasis and angiogenesis in term 
human placenta. 
 
ABSTRACT 
Introduction: Few studies have been carried out to investigate whether different areas of 
at term placenta express different amounts of markers involved in the placental 
haemostasis and angiogenesis. A possible  relationship between the expression of genes 
involved in the haemostasis and angiogenesis of human placenta has not been 
investigated. 
Materials and Methods: Twenty-eight fresh human placentas (35-41 weeks of gestation) 
from uneventful pregnancies  were dissected with two different methods. Quantity 
mRNA expression of TF, TFPI, TFPI-2, PAI-2, Anx V, VEGF, TM genes were evaluated 
by quantitative real time PCR system. Histology of each sample was graded . 
Results: Gene expression of all the considered markers was not significantly different 
(ANOVA test, p always >0.05) in each area, using both the different methods of 
dissection. A significant correlation (p<0.05) was found between the expression of TF 
and TFPI-2. TF and TFPI-2 were significantly (p<0.05) associated with VEGF, whereas a 
stronger association (p<0.01) was found between TFPI and TFPI-2. TFPI and TFPI-2 
were strongly associated with PAI-2 expression (p<0.01). 
Conclusions: In placentas with central cord insertion, gene expression is not dependent 
on the method of sampling site. A significant relationship between haemostasis and 
angiogenesis in at term placentas was shown. 
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 Key-words: placenta, TF, TFPI/TFPI-2, PAI-2, VEGF 
 
Abbreviations: Tissue factor (TF); Tissue Factor Pathway Inhibitor (TFPI); Tissue Factor 
Pathway Inhibitor-2 (TFPI-2); type-2 Inhibitor of Plasminogen Activator (PAI-2); 
Annexin V (Anx V); ThomboModulin (TM); Vascular Endothelial Growth Factor 
(VEGF). 
 
INTRODUCTION 
In some gestational disorders, pre-eclampsia and some forms of intrauterine growth 
restriction (IUGR), trophoblasts fail to express most of the endothelial markers Zhou 
1997, suggesting that this adhering phenotype switch is required for successful 
endovascular invasion and normal placentation (Fisher 1999). During pregnancy, the 
placenta is a putative source of tissue factor (TF), which is essential for embryogenesis 
(Erlich,1999), angiogenesis (Abe K, 1999), implantation and hemostasis (Parry 2000). 
The pro-coagulant tendency may render the placenta more susceptible to thrombotic 
risks, and excess activation of coagulation requires inhibitory mechanisms to avoid 
vascular occlusion (Aharon 2004). 
The inhibitor of the TF action pathway , tissue factor pathway inhibitor (TFPI) is highly 
expressed in placenta (Aharon 2004) and  inhibits factor Xa and factor VIIa-TF complex. 
TFPI is produced and secreted by endothelial cells. TFPI is expressed in placenta, mostly 
in megacaryocytes, endothelium of small vessels and macrophages (Edstrom CS 2000) 
TFPI-2 has been cloned from placenta  and is homologous to TFPI/lipoprotein-associated 
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coagulation inhibitor. TFPI-2 is a poor inhibitor of the TF/factor VIIa complex, as 
compared to TFPI, whereas is a strong inhibitor of factor Xa. TFPI-2 mRNA is widely 
expressed in various adult human tissue and especially abundant in placenta.  In the 
human placenta thombomodulin (TM) is located on the endothelium of placental vessel 
and also on the capital membrane of syncytiotrophoblast (Maruyama I 1985): a 
physiological role of TM and TF in the maintenance of maternal blood fluidity inside the 
intervillous space has been suggested.  
The type-2 inhibitor of plasminogen activator (PAI-2), a member of the serpin gene 
family is a fast- activing inhibitor of tissue-type and is expressed in trophoblast, 
monocytes, endothelial cells[Jensen, 1993]. It is known that it decreases in 
syncytiotrophoblast cells from IUGR placentas without or with preeclampsia. 
Annexin V (Anx V), a calcium-dependent anionic phospholipid-binding protein localised 
in many tissues, is abundant in the placenta, but low concentrations are present in blood. 
Anx V has a high affinity for anionic phospholipids, which binds in a Ca2+ dependent 
manner, inhibiting procoagulant reactions requiring anionic phospholipid. It is abundant 
on trophoblasts  and plays a pivotal role in the occurrence of  fetal loss in a murine model 
[Wang X 1999]. Vascular endothelial growth factor (VEGF) and its receptors have been 
localized in the placenta during early pregnancy at the time when the syncytiotrophoblast 
penetrates maternal tissues before vascular development (Wulff 2002). VEGF expression 
was localized in the trophoblast, suggesting that endothelial cell differentiation, migration 
and proliferation are essential steps for building the primary vascular network (Vuorela 
1999) During pregnancies complicated by preeclampsia and HELLP (Hemolysis, 
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Elevated Liver enzymes, and Low Platelets) syndrome, in which trophoblast invasion is 
disturbed, levels of VEGF are decreased (Zhou 2002). 
Placental architecture and blood flow are not uniform across the chorioallantoic human 
placental disk. Proximity to the umbilical cord, basal plate or chorionic plate may 
influence perfusion. Furthermore, syncytial knots and villous fibrin are more common 
near the chorionic surface as well as near the placental margin compared to other 
locations in the placenta.  
Although some studies investigated the expression of some genes involved in the 
occurrence of preeclampsia or IUGR (McCarthy C 2007, Roh 2005), to date few studies 
have been carried out to investigate whether different areas of at term placenta from 
uneventful pregnancies express different amounts of the above-mentioned markers in 
order to obtain information about homogeneity of expression. It has been postulated 
[Wyatt 2005] that if proximity to the cord was a key determinant of gene expression 
level, samples obtained near the marginally inserted cord would have lower expression 
than those obtained near the placental centre or from the margin opposite from the cord 
insertion.  
Aims of our study were: to evaluate the expression of each factor in different sections of 
at term placenta and to investigate a possible relationship between the expression of 
different genes. 
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 Materials and methods 
Placental tissue acquisition 
Twenty-eight fresh human placentas (35-41 weeks of gestation) from uneventful 
pregnancies were obtained immediately following uneventful spontaneous vaginal 
deliveries. Placentas were dissected in two spectral sections, the first was stored at -80 °C 
and then lyophylized, the second one was fixed in formalin 10%. In a first group of 
placentas (n=4), nine cubic sections (2x2 x all thickness cm), starting from the area 
closest to the cord insertion and proceeding toward the marginal area (Fig. 1) were 
obtained and stored at -80 °C. In a second group of placentas (n=8) 3 disks were 
obtained: chorionic surface, middle surface and basal surface. From each disk 3 samples 
(2x2x1 cm) were dissected starting from the cord insertion to lateral edge (Fig. 2). Two 
spectral pieces were cut from each section, one was stored at –80 °C and one was fixed in 
formalin 10%. A section from the chorionic to basal surface, was cut from other 17 
placentas and stored at -80°C. Umbilical cord insertion was defined as central if located 
within the third of the placental disk radius. Placentas with marginal or velamentous cord 
insertion were excluded. RNA purification, reverse transcription and quantitative PCR 
were found. The frozen samples of placentas were liophylized and total RNA was 
extracted by means of Invitrogen Trizol, Reagent (Invitrogen Corporation, Carlsbad, 
California) according to the manufacturer’s instructions. RNA was treated with DNAse 
(2 U /g of RNA), incubated in Gene Amp PCR System 2400 Thermal Cycler (Applied 
Biosystems, Warrington, UK) for 20 minutes at 37 °C, 3 minutes at 85 °C, 10 minutes at 
4 °C. Electrophoresis on a 1% agarose gel was performed to confirm the presence and 
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quality of RNA. RNA concentration and purity were determined by UV absorption at 260 
nm and 280 nm. Complementary DNA (cDNA) was prepared from the total RNA by 
means RT-PCR (Promega Reverse trascription system) (Promega, Madison, Wisconsin, 
U.S.A.). Quantity mRNA expression of TF, TFPI, TFPI-2, PAI-2, Anx V, VEGF, TM 
genes were evaluated by ABI 7700TM quantitative real time PCR system (Applied 
Biosystems, Warrington, UK) and compared to the human housekeeping 
glyceraldehydes-3-phosphate-dehydrogenase (GAPDH) gene. Primer and probe 
sequences were either supplied as a ready mix, TaqMan® Gene Expression Assay (VIC-
MGB for human GAPDH and FAM-MGB for human TF, human TFPI, human TFPI-2, 
human PAI-2, human Anx V, human VEGF, human TM). Each sample contained: 3 μl 
(0.04 g/l) of cDNA, Taqman Universal PCR Master Mix (12.5 μl), GAPDH primers 
and probe mix 20x (0.625 μl), target primers and probe mix 20x (1.25 μl) and RNAse 
free water to a volume of 25 μl. Amplification was performed for 10 min at 95 °C, 45 
cycles of  15 seconds at 95°C, 60 seconds at 60 °C. Gene expression levels were 
calculated using standard curves generated by serial dilutions of cDNA. A strong 
correlation between PCR efficiency of the internal control (GAPDH) and the target 
allowed the use of the ΔCt-method to quantify comparable mRNA levels. Three 
independent analyses were performed with replicates. 
The relative gene expression values were calculated by means of the comparative Ct 
method, using this arithmetic formula. Xn= K(1+E)-ΔCt ,where Xn= number of target 
molecules at cycle n; K= costant; E= efficiency of target assumed equal to efficiency of 
GAPDH; ΔCt= Ct,xX–Ct,R , where Ct,xX= threshold cycle for target amplification, Ct,R= 
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threshold cycle for GAPDH amplification. For amplicons designed and optimized 
according to PE Applied Biosystems guidelines (amplicon size < 150 bp), the efficiency 
is close to one. Assuming K=1, the amount of target, normalized to GAPDH is given by 
2-ΔCt  [Lyvak 2001]. 
Histological analysis 
Placental formalin- fixed paraffin-embedded sections (4 μm) were deparaffinized, 
rehydrated and stained with hematoxylin and eosin. The histology of each sample was 
graded based on Wyatt  parameters: (a) villous size (large, medium or small) (b) amount 
of fibrin deposits (sporadic, medium or increased) and (c) prevalence of syncytial knots 
(sparse, intermediate or common). Then, the slides were classified into grade I-III, with 
grade I characterized by larger villi, sporadic fibrin deposits and sparse syncytial knots, 
whereas grade III characterized by small villi, increased amounts of fibrin deposits and 
common syncytial knots. Grade II was used for those samples that did not fulfill the 
criteria for either grade I or grade III. (Wyatt 2005). 
 
Immunohystochemistry 
 
Placental formalin- fixed paraffin-embedded sections were deparaffinized and 
rehydrated. Endogenous peroxidase activity was blocked with Peroxidase Block (0.03% 
hydrogen peroxide containing sodium azide) (DakoCytomation) for 5 minutes at room 
temperature, followed by brief rinsing in distilled water. The sections were blocked for 
10 minutes at room temperature with a solution of 5 % normal goat serum, briefly rinsing 
in distillated water and then washed in TBS (DakoCytomation). Primary antibody for TF 
(American Diagnostica) 1:500 dilution was applied to cover specimen for one hour 
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followed by secondary antibody, peroxidase labelled polymer (DakoCytomation) for 30 
minutes. Enhanced liquid DAB+ substrate-chromogen solution (DakoCytomation)  was 
then applied to cover the specimen for 5 minutes. Then nuclei were displayed  by means 
hematoxylin. Chromogen substrate solution created an intense color deposit (brown) 
around the antigen in the sample. The sections were visualized by microscope.          
 
Statistical Analysis 
Statistical analysis was performed by means of SPSS. All the results are presented as 
mean +SD . Differences between groups were analyzed by means of Mann-Whitney 
method. ANOVA was used to compare three or more independent samples. Correlation 
between parameters was assessed using the Spearman rank test. Values of p <0.05 were 
considered significant. 
 
Results 
Gene expression of all the considered markers (TF, TFPI, TFPI-2 PAI-2, Anx V, VEGF, 
TM) was not significantly different (ANOVA test, p always >0.05) in the area closest to 
the cord insertion site compared to each of the peripheral ones , according to the method 
of dissection shown in Figure 1 (Tab 1). 
Histological analysis showed, as expected, [Wyatt 201] grade I most prevalent at site 1A, 
which represents the medio-basal region. Histological changes for grade I are large villi, 
sporadic fibrin deposits and sparse syncytial knots. Grade III , as expected, was the most 
prevalent at site 3C, which represents the lateral-chorionic region. Histological features at 
this side included small villi, prevalent fibrin deposits and frequent syncytial knots.  
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We hypothesized that another method of sampling sections could show a difference in the 
expression of these markers, according to the findings of histological analysis. Thus, 
placental samples were obtained as shown in Figure 2.  
Gene expression of chorionic, maternal and intermediate areas was performed in all 9 
samples  depicted in Figure 2. Each sample did not show a significantly different 
expression of all the markers (Table 3, ANOVA test, p always >0.05) , as compared to 
any other sample . 
Thus, we investigated a possible relationship between these markers in sections closest to 
the insertion cord of 20 normal placentas. 
As showed in Figure 3, a significant correlation (p<0.05) was found between the 
expression of TF and its inhibitor TFPI-2, mainly produced by placenta. In addition, TF 
and TFPI-2 were both significantly (p<0.05) associated with a marker of angiogenesis, 
VEGF, whereas a stronger association (p<0.01) was found between TFPI and TFPI-2. 
Both pathways inhibitors, TFPI and TFPI-2 , were strongly associated with PAI-2 
expression (p<0.01). 
 
Discussion 
Although many authors have investigated human at term placenta, few data are available 
about a possible different expression of markers, depending on the sampling site. To date, 
it is not clear whether studies of gene expression have to be performed using a certain 
method for dissection of placenta. 
In order to better define how to obtain placenta samples for following studies aimed at 
comparison of placentas from uneventful and complicated pregnancies, we first decided 
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to compare two different methods of dissection. In addition, we would like to verify by 
recruiting a relatively high number of normal placentas, the biological variability in the 
gene expression. Two different methods for dissecting placenta were used and, although 
histology showed, as in previous similar reports, [Wyatt 2001] the presence of different 
grades within normal placenta, no significant differences were observed in the gene 
expression. Wyatt and coll recently showed that the gene expression of VEGF  was 
enhanced in the subchorionic lateral border compared to medial basal site. 
At variance with Wyatt and coll, we first lyophilized the samples and furthermore used 
only placentas with central cord insertion. This procedure allowed us to obtain sections 
measuring exactly 2x2x1 cm. This could explain our different results. 
Many studies have been reported in literature about TF/TFPI expression in placentas 
from pregnancies complicated by IUGR or preeclampsia, although it is not clearly stated 
usually which sections of placentas have been used. Some studies  analysed the TF/TFPI 
expression balance mainly in the villous trophoblast [ Estellés 1994, Aharon 2004], 
although a recent report focuses on the expression of whole sections of the placenta 
[Aharon 2005]. Placental TFPI is decreased in gestational vascular complications and can 
be restored by maternal enoxaparin treatment. 
However, TF is produced and induced in monocytes, endothelial cells, fibroblasts, and 
macrophages, in addition to villous throphoblasts. We first investigated the gene 
expression in the placenta “in toto” (Fig 1), searching for possible different expression 
depending on the sampling site.  
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We were not able to show any difference between areas near cord insertion and each of 
the other sections.  Then, another method of dissection (Fig 2 )  was used, but also in this 
case no different expression among the different samples analyzed was recorded. 
PAI -2 is mainly expressed by human placenta tissue [Astedt, 1986], but also by 
macrophages, and a possible role in placental cell invasion in the uterus has been invoked 
[Zhou, 1997]. As for TF/TFPI,  PAI-2 antigen has been previously studied in term 
healthy placentas  and in those from preeclamptic women. We decided to study the whole 
section of normal placentas. It is clearly demonstrated that TF is expressed  by 
throphoblasts in addition to placental macrophages or fibroblasts [Aharon 2004]. Our 
data show that TF is expressed in the whole section of placenta; in addition, 
immunoistochemical studies (data not shown) clearly demonstrate the localization of TF 
in at term syncytiotrophoblasts and in the adventitial layer of blood vessels. 
We found a direct relationship between expression of TFPI or TFPI-2 and PAI-2. 
Furthermore, TFPI-2 expression is directly related also to TF.  
These relationships could be responsible , at least in part, for local haemostasis in 
placentas from normal pregnancies. In agreement with Aharon and coll, who studied 
syncytiotrophoblasts culture , we can hypothesize also in at term placentas, the presence 
of a hemostatic balance critical for normal placental function and pregnancy outcome. 
Our data show a relationship between VEGF and TF and TFPI-2 expression. Previous 
studies demonstrated that VEGF can stimulate the production of TF and, furthermore, 
that TF can stimulate expression of VEGF in human umbilical vein endothelial cells. 
The presence of a relationship between TF and VEGF in at term human placentas was 
observed . In addition, we observed a relationship between VEGF and TFPI-2, suggesting 
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the presence of a counterbalance of the angiogenesis by TFPI-2, that might have an 
important role to maintain intervillous blood flow. These data data are in agreement with 
those by  Xu et al., who demonstrated in endothelial cells that VEGF induces both time- 
and dose-dependent increase in TFPI-2 mRNA.   
In conclusion, our data show  that sampling sites does not influence placental transcript 
expression . Studies aimed at the evaluation of the relationships here described  in clinical 
conditions, as  preeclampsia and IUGR responsible for an imbalance in the  placental 
development,  are needed. 
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 Figure  1 
First method of  placental sampling sites (N= umbilical cord insertion site) 
 
 
Figure  2 
Second method of placental sampling sites. From each section 9 samples were obtained 
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Figure 3 
 
Statistically significant correlations  
Spearman’s correlation coefficients (n=21 placentas ) 
*p ≤ 0.05 level. ** p ≤ 0.01 level 
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 Table 1Gene expression in placenta , according to sampling sites as reported in Fig 1( 
ANOVA, p always > 0.05) 
  TF 
 [ 2-ΔCt] 
TFPI 
[ 2-ΔCt] 
TFPI-2 
[ 2-ΔCt] 
PAI-2 
[ 2-ΔCt ] 
ANX V 
[ 2-ΔCt] 
VEGF 
[ 2-ΔCt] 
TM 
[ 2-ΔCt] 
N 2.35 ± 0.41 11.92 ± 15.31 362.48 ± 774.13 0.28 ± 0.20  3.52 ± 0.87 0.10 ± 0.07 0.10 ± 0.06 
A 2.33 ± 1.71 6.80 ± 5.07 242.18 ± 181.20 0.20 ±  0.05 5.12 ± 2.18 0.66 ± 0.85 0.07 ± 0.04 
B 2.83 ± 0.63 6.12 ± 4.11 82.71 ± 67.37 0.16 ± 0.08 4.09 ± 2.22 0.22 ± 0.24 0.09 ± 0.09 
C 1.80 ± 1.48 18.91 ± 25.22 98.86 ± 84.09 0.29 ± 0.20 4.16 ± 1.74 0.10 ± 0.03 0.08 ± 0.04 
D 2.53 ± 0.63 33.03 ± 5.26 1045.22 ± 1584.63 0.40 ± 0.69 6.06 ± 2.12 0.55 ± 0.62 0.28 ± 0.22 
E 2.09 ± 1.18 19.73 ± 12.07 1293.06 ± 2241.37 0.63 ±  0.33 4.62 ± 2.44 0.53 ± 0.51 0.33 ± 0.34  
F 3.55 ± 2.86 9.47 ± 6.78 234.25 ± 221.79 0.25 ± 0.12 5.71 ± 2.73 0.60 ±  0.45 0.06 ± 0.05 
G 1.04 ± 0.41 6.83 ±  4.62 140.37±  129.37 0.75 ± 0.62 3.91 ± 0.59 0.52 ± 0.64 0.17 ± 0.25 
H 6.50 ± 4.68 5.15 ± 3.35 444.33 ± 745.41 0.18 ± 0.35 5.65 ± 0.57 0.81 ± 0.37  0.12 ± 0.04 
 
Table 2. Gene expression in placenta , according to sampling sites as reported in Fig 2 
(ANOVA, p always >0.05) 
 
  TF 
[ 2-ΔCt] 
TFPI 
[ 2-ΔCt] 
TFPI-2 
[ 2-ΔCt] 
PAI-2 
[ 2-ΔCt ] 
ANX V 
[ 2-ΔCt] 
VEGF 
[ 2-ΔCt] 
TM 
[ 2-ΔCt] 
1C 0.49 ± 0.37  9.08 ± 6.91  188.23 ± 
257.10 
1.41 ± 
1.28 
10.65 ± 12.46 0.21 ± 0.28 0.29 ± 0.35 
1B 0.42 ± 0.33  9.36 ± 6.56  246.32 ± 
422.25 
3.04 ± 
3.13 
9.90 ± 11.03  0.14 ± 0.16 0.24 ± 0.30 
1A 0.58 ± 0.39 9.43 ± 6.71 385.29 ± 
699.29 
1.93 ± 
1.42 
13.10 ± 19.17 0.27 ± 0.34 0.24 ± 0.29 
2C 0.49 ± 0.36 13.28 ±  8.14 140.71 ± 
188.56 
1.81 ± 
1.46 
13.17 ± 13.52 0.11 ± 0.11 0.29 ± 0.40 
2B 0.62 ± 0.56 11.71 ± 8.80 251.66 ± 
452.43 
2.67 ± 
2.49 
15.75 ± 16.89 0.42 ± 0.76  0.77 ± 0.49 
2A 0.78 ± 0.65 9.65 ± 7.60 252.40 ± 
457.37 
2.20 ± 
2.30 
9.55 ± 7.91 0.24 ± 0.32 0.17 ± 0.19 
3C 0.52 ± 0.42 12.38 ±  8.41 97.04 ± 
105.00 
2.32 ± 
2.04 
16.23 ± 21.93 0.16 ± 0.21 0.30 ± 0.45 
3B 0.58 ± 0.45 11.20 ±  8.42 157.41 ± 
223.30 
2.96 ± 
3.22 
22.90 ± 31.86 0.16 ± 0.23 0.31 ± 0.41 
3A 0.54 ± 0.31 10.93 ± 7.21 59.02 ± 62.58 2.73 ± 
2.57 
16.44 ± 15.59 0.20 ± 0.35 0.34 ± 0.46 
Submission in process  
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App. 3 
 
EXPRESSION PROFILE OF DIFFERENT COAGULATION 
MARKERS IN HUMAN PLACENTAS FROM COMPLICATED 
PREGNANCIES 
 
 
INTRODUCTION 
Pre-eclampsia and IUGR are a serious complication of pregnancy that are potentially life 
threatening for both the mother and baby. 
Risk factors for preeclampsia have been analyzed in a recent systematic review and 
include: a previous history of preeclampsia, primiparity, obesity, family history 
of preeclampsia, multiple pregnancies, and chronic medical conditions such as long-term 
hypertension or diabetes. 
The hypothesized etiologic factors could be classified, at least, into 4 groups: genetics, 
immunologic, nutrition and infections, and interactions among them. The hypothesized 
pathophysiologic alterations are numerous, including failure of invasion of the 
trophoblast cells, oxidative stress, endothelial dysfunction, aberrations in calciotrophic 
hormones, release of growth factors, and antiagiogenic proteins among others. These 
changes may lead to proteinuria and hypertension and other phenotypes of the clinical 
syndrome of preeclampsia. 
Intra uterine growth retardation is usually caused by uteroplacental vascular insufficiency 
and results in chronic fetal hypoxia, abnormal placental morphology, eccentric cord 
insertion.  As such, local tissue hypoxia in the placental bed has been proposed as the 
mechanism limiting trophoblast  invasion into the spiral arteries. 
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The placenta is a unique organ with dual blood circulation functioning throughout fetal 
development. The architecture and functions of the placenta, where maternal blood flows 
in the intervillous space, present haemostatic problems, mainly the risk of haemorrhage. 
Placental throphoblasts express and produce coagulation components, partecipating not 
only in haemostatsis, but also in the placental vascular development and differentiation. 
The expression of tissue factor (TF), membrane phosphatidylserine and fibrin render the 
throphoblasts pro-coagulan, thus compromising the risk of bleeding while exposing the 
placenta to pro-thrombotic risks. Local inhibitory mechanism TFPI-1 and TFPI-2, 
thrombomodulin, annexin V and the fibrinolytic system-limit coagulation activation and 
fibrin deposition. Pregnancy complications have been associated with abnormalities in 
the functions of these inhibitors. Haemostatic processes in placental cells change 
throughout gestation and are affected by the changing requirements of the organs. 
The aim of our study was to investigate the associations of the expression of some 
placental factor in women with successful pregnancy outcome and in women with onset 
of the preclampsia or other complications of the pregnancy.  
 
MATERIAL AND METHODS 
Placental samples of women with successful pregnancy outcome and women with 
preclampsia or other complications of the pregnancy; delivery during 35-42 weeks of 
gestations.  Samples were frozen to  –80 °C.  
The frozen samples of placentas were liophylized and total RNA was extracted by means 
of InvitrogenTrizol, Reagent, according to the manufacturer’s instructions. RNA was 
treated with DNAse (2 U of RNA), incubated in Gene Amp* PCR System 2400 Thermal 
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Cycle (Applied Biosystems) for 20 minutes at 37 °C, 3 minutes at 85 °C, 10 minutes at 4 
°C. Electrophoresis on a 1% agarose gel was performed to confirm the presence and 
quality of RNA. RNA concentration and purity were determined by UV absorption at 260 
nm and 280nm. Complementary DNA (cDNA) was prepared from the total RNA by 
means RT-PCR (Promega Reverse trascription system). 
mRNA expression 
Quantity mRNA expression of TF, TFPI, genes were evaluated by ABI 7700TM 
quantitative real time PCR system (Applied Biosystems, Warrington, UK) and compared 
to the human housekeeping glyceraldehydes-3-phosphate-dehydrogenase (GAPDH) 
gene. Primer and probe sequences were either supplied as a ready mix (for human 
GAPDH and for human TF, human TFPI). Each sample contained: 3 μl of cDNA, 
Taqman Universal PCR Master Mix (12.5 μl), GAPDH primers and probe mix 20x 
(0.625 μl), target primers and probe mix 20x (1.25 μl) and RNAse free water to a volume 
of 25 μl. Amplification was performed for 10 min at 95 °C, 45 cycles of  15 seconds at 
95°C, 60 seconds at 60 °C. Gene expression levels were calculated using standard curves 
generated by serial dilutions of cDNA. A strong correlation between PCR efficiency of 
the internal control (GAPDH) and the target allowed the use of the ΔCt-method to 
quantify comparable mRNA levels. Three independent analyses were performed with 
replicates. 
The relative gene expression values were calculated using the comparative Ct method. 
the amount of target, normalized to GAPDH is given by 2-Δ 
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RESULT 
TF and TFPI expression were evaluated in 9 preeclamptic women  and in 21 controls. 
Expression of TF and of the inhibitor (TFPI) were minor in the patients with pregnancy 
complicated by PE. The mean of TF in patients with PE is  0,88 (SD 1,04); in the 
uneventful pregnancies the mean is 1,7 (SD 1,23); the mean of TFPI in group of PE is 
7,63 (SD 10,61); in control with uneventful pregnancy the mean is 39,89 (SD 51,35). 
TFPI values in pregnancy complicated by PE result fivefold inferior vs uneventful 
pregnancy. 
 
DISCUSSION 
The incidence of preclampsia (PE) is 5-10% of all pregnancies and this disease is a major 
cause of feto-maternal morbidity/mortality. The real cause of PE is unknown. 
Preclampsia was defined as maternal blood pressure of more than 140/90 mm Hg with 
proteinuria (.300 mg/24 h or 12 on single urine sample) and edema. Several causes  
(genetic, nutritional, immunologic, infectious) and pathological mechanism were 
proposed (abnormal placentation, oxidative stress, endothelial damage). In any case all 
these causes and all these mechanism may interact and all may be responsible of the 
syndrome. Many case-control studies suggest a possible correlation between   pro-
thrombotic factors and poor outcome of pregnancy, while other authors don’t show this 
association. The real mechanism responsible of the syndrome were not well known. PE, 
IUGR, placental abruption, fetal death were linked to a low flow in feto- maternal 
circulation because deficit of throphoblastic invasion and remodelling of spiral uterine 
arteries. In the last years several studies shown that the thrombotic factors acquired or 
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hereditary may cause a low blood flow leading thrombosis in feto-placental unit. 
Evidences to support this hypothesis derived principle from association of study which 
revealed high prevalence of pro-thrombotic factors in coorti of pregnant with poor out 
come of pregnancy.    
Even if these studies were conducted with some cases, these dates were utilized for the 
women with poor outcome of the pregnancy; these women received treatment with 
heparin in successive pregnancy. Others studies didn’t show high levels of thrombotic 
factors in population with poor outcome. For these authors the pro-thrombotic factors the 
utility of the heparin therapy will be appropriate only after the unequivocally benefit 
showed by randomize clinical trial. 
In this stdudy RNA was extracted and then cDNA was obtained by means RT-PCR  and 
the expression of TF, TFPI, TFPI-2 was evaluated. The result must be correlated with 
successive studies which will evaluate expression of these factor in different areas of 
placenta syncitio and extracellular matrix because we now have dates given from all 
placental tissue. We observed a minor genetic expression of TF, but the potential  
thrombosis is secondary to the low levels of the TFPI. 
The value of genetic expression of some placental thrombotic factors and the blood or 
urinary sample of these would be utilized to evaluate the start and or the severity of 
preeclampsia /IUGR. Naturally if we know the value of these factors we will utilize in 
high risk population for prevention of thrombotic accident. 
We want in the future to evaluate genic expression of this and other prothrombotic factors 
in different histological placental sections such as syncytiotrophblast and extracellular 
matrix. 
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App. 4 
 
PREGNANCIES COMPLICATED FROM PRECLAMPSIA and IUGR: EXPRESSION  
 
PROFILE OF COAGULATION MARKERS IN PLACENTAS  
 
 
Introduction 
Preeclampsia is a mulisystem disease of unknown etiology associated with increased 
perinatal/maternal morbidity and mortality. Although preeclampsia is commonly 
associated with intrauterine fetal growth restriction (FGR), small-for gestational-age 
infants (SGA) can also be observed without hypertensive disease, and the severity of 
FGR is correlated with the degree of placental infarction and impaired placental nutrient 
transport.  
Physiologic changes in the coagulation and fibrinolytic systems are known to result in an 
increased susceptibility of pregnant women to thrombotic disorders and the formation of 
fibrin deposits, which can lead to a reduction in nutrient transport across the placenta 
(Estellés, 1994). 
In a preliminary study, performed on a group of 28 placentas from uncomplicated 
pregnancies, we found a direct relationship between expression of TFPI or TFPI-2, two 
inhibitors of TF, and PAI-2. Furthermore, TFPI-2 expression was directly related also to 
TF. These relationships showed a correlation between coagulation and fibrinolytic 
systems and could be responsible, at least in part, for local haemostasis in placentas from 
normal pregnancies. In the same study was found a relationship between TF and TFPI-2 
and VEGF, one of the principal regulators of angiogenesis (Wulff, 2003). So in placenta 
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from uncomplicated pregnancies there was a relationship between haemostasis and 
angiogenesis. 
The expression of TF renders the trophoblasts pro-coagulant thus compromising the risk 
of bleeding while exposing the placenta to pro-thrombotic risks. Local inhibitory 
mechanisms, TFPI and TFPI-2, TM, Anx V, and the fibrinolytic system, limit 
coagulation activation and fibrin deposition. Pregnancy complications have been 
associated with abnormalities in the functions of these inhibitors (Lanir, 2003). 
Human placenta is characterized by deep trophoblast invasion and complete remodeling 
of maternal vasculature by digestion of upper parts of myometrial spiral arterioles. 
VEGF, PlGF, Ang-1 and Ang-2 appear not only to regulate vascular development and 
remodeling during placentation but also act as grwth factors for driving growth and 
differentiation processes such as trophoblast invasion and maturation failure of 
trophoblast invasion is associated to preeclampsia and IUGR. .(Wulff, 2003). 
The aim of this study is to know if the previously described relationships, found in 
uncomplicated pregnancy, fail to exist in placentas from preeclamptic or FGR pregnancy. 
We can hypothesize the presence of a hemostatic balance critical for normal placental 
function and pregnancy outcome. 
In order to verify our hypothesis we first evaluated the expression of factors involved in 
haemostatic and angiogenic mechanisms in these complicated pregnancy and compared 
them with expression levels in uncomplicated one. 
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 Materials and methods 
Placental tissue acquisition 
Placentas were obtained from four groups of pregnant women: a control group (n=21) 
and three groups whose pregnancies were complicated by normotensive IUGR (n=20), 
PE (n=10) or PE+IUGR (n=17). Control cases were not complicated by IUGR, PE or 
other conditions such as HELLP, diabetes mellitus and renal disease. PE was defined by 
maternal proteinuria >300mg/L in a 24 h collection together with blood pressure in a 
previously normotensive woman >140/90 mmHg on two or more occasions. IUGR was 
identified by newborn weight <3rd percentile of appropriate birth weight for gestational 
age (SMILA Neonatal standards for North-East Italy; Montecatini SEP 1996) (Table 1). 
Placental tissues were sectioned into samples of approximately 2cm x 2cm x whole 
thickness taken from the area closest to the cord insertion  and stored at -80 °C. 
From some placenta in complicated and uncomplicatrd groups (n=8 from PE, n=5 from 
C) immediately after delivery cytotrophoblasts were isolated. 
Syncytiotrophoblats cell culture 
Cells were isolated as previously described (Kliman 1986) with some modifications. 
Viollus tissue from the deciduas side was cut into small pieces. Tissue (∼ 50g) was 
washed with 0.9% NaCl at room temperature.and digested by three steps in warmed 
Hanks’ solution (Cambrex..) containing 0.125% trypsin (Sigma…) and 0.2 mg/ml DNase 
I (Sigma …). Supernatant with 10% FCS (Cambrex..)was layered on Histopaque 1077 
(Sigma) and centrifugated (1200 rpm for 20minutes). Cells in the median layer were 
separated, washed and plated on culture plates (35mm) pre-coated with fibronectin 
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(VWR..). Cells were cultured in M199 (Cambrex) supplemented with 50 μg/ml 
gentamicin, 1% penicillin-streptomycin (cambrex), 20% (vol/vol) FCS and incubated in 
humidified 5% CO2-95% air at 37°C. After the first 24 hours, apoptotic 
syncytiotrophoblasts were washed out and the remaining cytotrophoblasts differentiated 
and matured in culture into new generation of syncytiotrophoblat. After 14 days cells 
were characterizated with cytokeratin 7 by….. 
From cytokeratin 7 bind cells RNA was extract by means of Invitrogen Trizol, Reagent 
(Invitrogen Corporation, Carlsbad, California) according to the manufacturer’s 
instructions. 
RNA purification, reverse transcription and quantitative PCR 
The frozen samples of placentas were liophylized and total RNA was extracted by means 
of Invitrogen Trizol, Reagent (Invitrogen Corporation, Carlsbad, California) according to 
the manufacturer’s instructions. RNA was treated with DNAse (2 U /μg of RNA), 
incubated in Gene Amp PCR System 2400 Thermal Cycler (Applied Biosystems, 
Warrington, UK) for 20 minutes at 37 °C, 3 minutes at 85 °C, 10 minutes at 4 °C. 
Electrophoresis on a 1% agarose gel was performed to confirm the presence and quality 
of RNA. RNA concentration and purity were determined by UV absorption at 260 nm 
and 280 nm. Complementary DNA (cDNA) was prepared from the total RNA by means 
RT-PCR (Promega Reverse trascription system) (Promega, Madison, Wisconsin, U.S.A.). 
Quantity mRNA expression of TF, TFPI, TFPI-2, PAI-2, Anx V, TM, VEGF, PlGF, 
Ang-1, Ang-2 genes were evaluated by ABI 7700TM quantitative real time PCR system 
(Applied Biosystems, Warrington, UK) and compared to the human housekeeping 
glyceraldehydes-3-phosphate-dehydrogenase (GAPDH) gene. Primer and probe 
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sequences were either supplied as a ready mix, TaqMan® Gene Expression Assay (VIC-
MGB for human GAPDH and FAM-MGB for human TF, human TFPI, human TFPI-2, 
human PAI-2, human ANX V, human TM, human VEGF, human PlGF, human Ang-1, 
human Ang-2). Each sample contained: 3 μl (0.04 μg/μl) of cDNA, Taqman Universal 
PCR Master Mix (12.5 μl), GAPDH primers and probe mix 20x (0.625 μl), target primers 
and probe mix 20x (1.25 μl) and RNAse free water to a volume of 25 μl. Amplification 
was performed for 10 min at 95 °C, 45 cycles of  15 seconds at 95°C, 60 seconds at 60 
°C. Gene expression levels were calculated using standard curves generated by serial 
dilutions of cDNA. A strong correlation between PCR efficiency of the internal control 
(GAPDH) and the target allowed the use of the ΔCt-method (14) to quantify comparable 
mRNA levels. Three independent analyses were performed with replicates. 
Statistical Analysis 
Statistical analysis was performed by means of SPSS. All the results are presented as 
mean +SD . ANOVA was used to compare two or more independent groups. Correlation 
between parameters was assessed using the Spearman rank test. Values of p <0.05 were 
considered significant. 
 
Results 
Our data show that haemostatic factors TF, TFPI, Anx V and PAI-2 are respectively 2, 8, 
1.5 and 5 fold less expressed in placentas from complicated pregnancy (n=47) than  in 
control (n=21) ones (p<0.01). On the other hand angiogenic markers (VEGF, PlGF, Ang-
1; Ang-2) were not significantly different. 
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Dividing the complicated group in PE with or without FGR group (n=27) and FGR group 
(n=20), we found that in both groups TF, TFPI and PAI-2 were significantly (p≤0.01) 
lower expressed in respect of controls. In PE group TF, TFPI and PAI-2 expression were 
respectively 0.5, 6 and 4 fold lower than in control; in FGR group they were respectively 
3, 2 and 6 fold lower than in control. Anx V was 2 fold less expressed in FGR than in 
control (p=0.01), but in PE the expression was not statically different, on the other hand 
TM was 2 fold higher than in control(p<0.01), but not in FGR.    
In PE group Ang-1 and Ang-2 were 2 fold higher expressed than in control (p<0.01). In 
FGR group Ang-2 was 3 fold lower than in control.   
Syncytiotrophoblasts data. 
Syncytiotrophoblasts cells data show that TFPI-2 was 5-fold less expressed in 
complicated group in respect of control (p<0.05). The other haemostatic factors were not 
significantly lower expressed. Among angiogenic factors only VEGF was significantly 
lower (10 fold) expressed in complicated group (p<0.05). 
Correlations between haemostatic factors 
In all complicated groups there was a significant (p<0.05) direct correlation, as in control 
group, between TF and its inhibitors: TFPI and TFPI-2. Furthermore, both the inhibitors 
of TF were directly correlated with PAI-2 (p<0.01). But analyzing separately the three 
complicated groups we found that in PE and in FGR groups the correlations between TF 
and its inhibitors fail to exist. (A new correlation was foun in PE group between TFPI 
and Anx V). 
Correlations between angiogenic factors 
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About angiogenic mechanisms in placentas from uncomplicated pregnancies we observed 
a significant direct correlation between Ang-1 and Ang-2 (p<0.05), PlGF and Ang-2 
(p<0.05). 
In PE there was significant indirect correlation (p<0.05) between Ang-1 and PlGF, this 
correlation was not found in FGR group.  
Correlations between haemostatic and angiogenic mechanisms. 
In placentas from uncomplicated pregnancies we observed a significant direct correlation 
between VEGF, TF and TFPI-2 (p<0.05). On the other hand, PlGF was not correlated 
with these two but there was a significant direct correlation (p<0.05) with TFPI, PAI-2 
and Anx V. Ang-1 and Ang-2 were significant correlated with TFPI (p<0.05). TF was 
significantly correlated with Ang-1 (p<0.05) but not with Ang-2.  TFPI-2, PAI-2 and 
PlGF were significantly correlated with Ang-2 (p<0.05) but not with Ang-1. 
Analyzing the correlations between angiogenic and haemostatic mechanisms in 
complicated pregnancies we found that VEGF was not correlated with anyone of the 
analyzed haemostatic markers. In the complicated groups separately we found in PE with 
or without FGR a significant direct correlation between PlGF and TFPI-2 (p<0.05), PAI-
2 (p=0.01), Anx V (p<0.01). Also in FGR group there was a significant direct correlation 
between PlGF and PAI-2 (p<0.05). In all complicated groups (PE, PE+IUGR, IUGR) 
Ang-1 was significantly directly correlated with TF. In PE and PE+IUGR there were 
significant indirect correlation (p<0.05) between Ang-1 and PlGF and PAI-2, these 
correlation were not found in IUGR group. Ang-2 was correlated only with TF in IUGR 
group. 
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Gene 
Symbol Assay ID Context Sequence Chromosome 
TF Hs00175225_m1 CCTGGAGACAAACCTCGGACAGCCA 1 
TFPI Hs00196731_m1 TTGCAACAAGAAAAGCCAGATTTCT 2 
TFPI2 Hs00197918_m1 ACCAAAGAAAATTCCATCATTTTGC 7 
PAI 2 Hs00234032_m1 AGATGGCCAAGGTGCTTCAGTTTAA 18 
ANXV Hs00154054_m1 GCCATGGCACAGGTTCTCAGAGGCA 4 
VEGF Hs00173626_m1 ATGCCAAGTGGTCCCAGGCTGCACC 6 
TM Hs00264920_s1 GAGCAGCAGTGCGAAGTGAAGGCCG 20 
ANGPT1 Hs00375823_m1 GAAAAAAACAGTTTATTAGAACATA 8 
ANGPT2 Hs01048043_m1 CCACATCAAACTCAGCTAAGGACCC 8 
PlGF Hs01119262_m1 CGAATGCCGGCCTCTGCGGGAGAAG 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Weeks' gestation Birth wt (g) Percentile 
Placenta wt  
(g) 
Maximal 
diastolic 
blood 
pressure 
(mm Hg) 
Proteinuria 
mg/L in 24 h 
PE 
(n=10) 33±3,36 2117±893,25 25<p<50 600±100 95±6 1474±1083,99 
PE+IUGR 
(n=17) 33±2,56 1251±449,87 3<p<10 314±149 98±10 9860±12901,37 
IUGR 
 (n=20) 33±4,84 1373±765,13 3 300±212 99±11 <300 
C  
(n=21) 39±1,73 3319±445,08 50<p<90 506±70,71 76±7 <300 
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PLACENTA, THROMBOPHYLIA, DOPPLER 
Pre-eclampsia is a serious complication of pregnancy that is potentially life threatening 
for both the mother and baby. It encompasses a number of abnormalities that may be 
present in other clinical conditions. A placenta is essential for the development of pre-
eclampsia and can be important in the pathogenesis of pre-eclampsia. Normal pregnancy 
is associated with remodelling of the maternal spiral arteries, which deliver blood to the 
placental villous space. Remodelling involves invasion by placental cytotrophoblasts that 
cause the maternal spiral arteries to lose their smooth muscle and become capacitance 
vessels; this process, known as placentation, is complete by 20 weeks of pregnancy. Poor 
placentation is associated with small-for-gestational-age fetuses and some cases of pre-
eclampsia. It is thought that poor placentation can result in a hypoxic placenta that 
releases 'toxic substances' into the maternal circulation, contributing to the maternal 
syndrome. A number of candidate 'toxic substances' have been proposed, but none is 
universally raised in pre-eclampsia. Although the placenta is necessary for the 
development of pre-eclampsia, the extent to which placental abnormalities contribute to 
the condition varies. It is becoming apparent that maternal constitutional factors may also 
be important in this syndrome. Underlying hypertension, diabetes and obesity strongly 
predispose to pre-eclampsia. However, a continuum of risk may exist for blood pressure, 
bodyweight, glucose and lipids, which, in combination with each other and some degree 
of placental abnormalities, may lead to the development of pre-eclampsia.  
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A regular placental invasion and a normal placental morphology are indispensable for a 
normal pregnancy and a normal fetal development. In International literature there are 
many papers on placenta and its genetic, biochemical and hormonal aspects; many 
reports outline the relationship between placenta and pregnancy’ s diseases or its 
relationship with fetal malformation. Today we again don’t know the modifications 
directly responsible of some disease (IUGR and PE) and of the fetal malformations;  we 
will try to found the mechanism responsible of these diseases and its link with placenta 
valuing the correlation of anomalies Doppler ultrasonographic waves with the expression 
of the placental factors.  
The physiological changes that occur during pregnancy create a hypercoagulable milieu. 
This hypercoagulable state is thought to be protective, especially at the time of labor, 
preventing excessive hemorrhage. The presence of hereditary or acquired causes of 
thrombophilia during pregnancy tilts the balance in favor of unwanted venous 
thromboembolism and adverse pregnancy outcomes due to vascular uteroplacental 
insufficiency. These adverse pregnancy outcomes include recurrent pregnancy losses, 
intrauterine fetal death, intrauterine growth retardation, preeclampsia and placental 
abruption. Much of the current data with regards to the association of the different 
thrombophilias and pregnancy-related complications are based on retrospectively 
designed studies. Recurrent pregnancy loss affects 1% to 3% of women of reproductive 
age, and a large proportion of these losses remain unexplained. Thrombophilic defects 
were found in 49% to 65% of women with pregnancy complications compared with 18% 
to 22% of women with normal pregnancies, suggesting a 3- to 8-fold increase in risk 
 
 101
Few studies have documented thrombotic lesions observed on the pathologic examination 
of the placenta in women with severe pregnancy complications. Moreover, a significantly 
higher rate of factor V Leiden and prothrombin G20210A gene mutations have been 
found in placentas with thrombotic events compared with normal placentas. In addition, 
clinical studies have been performed, using Doppler ultrasonography, to assess the 
uterine placental circulation in women with thrombophilia. Most of the Doppler studies 
of the umbilical and uterine arteries in pregnancies with thrombophilia were performed in 
women with antiphospholipid antibodies. Few Doppler studies also suggest improved 
uterine placental circulation when women with thrombophilia received 
thromboprophylaxis. 
References 
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We show the adverse outcome in women with thrombophilia and bilateral uterine artery 
notches considering the decreased uteroplacental blood flow during pregnancy in carriers 
of prothrombotic mutations. 
 
App. 5  
Outcome in women with thrombophilia and Bilateral uterine artery notches: our 
experience 
 
Discrepancies about a possible relationship between prothrombotic mutations and a 
decreased uteroplacental blood flow are present in literature. We prospectively evaluated 
a cohort of pregnant women (n = 41) with bilateral uterine artery notches and found that 
women with inherited thrombophilia showed a sixfold higher risk to have an adverse 
outcome than women without. 
Women with decreased uteroplacental blood flow during pregnancy have been found to 
be carriers of prothrombotic mutations, but there are some discrepancies on this issue 
(1,2). We prospectively evaluated a group of women with bilateral notch of uterine 
arteries at 23 weeks of gestation. The presence of inherited causes of thrombophilia was 
investigated. FV Leiden, FIIA20210 mutations were evaluated during pregnancy, and 
levels of natural inhibitors (protein C, protein S, antithrombin) were measured 3 
months after the delivery. Forty-one women (mean age 29.1 ± 4.9 years) were enrolled 
and fetomaternal outcome was recorded. They were followed at the University “Federico 
II” of Naples and underwent the same obstetric surveillance during the current 
pregnancy. All women were tested for natural anticoagulants 3 months after the delivery. 
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Institutional Review Board approval was obtained. Gravidity and parity (mean ± SD) 
were 1.5 ± 0.7 and 0.5 ± 0.7, respectively. Overall, 21 (51.2%) women were nulliparous. 
Among the parous women, 3 (15%) reported a previous small-for-gestational age 
newborn, 3 (15%) an intrauterine fetal death, 6 (30%) early pregnancy losses, and 8 
(40%) an uneventful pregnancy. None of the women suffered from chronic or preexisting 
disorders, such as diabetes or hypertension. Six (14.6%) of the 41 women showed 
inherited thrombophilia (2 heterozygous for FV Leiden, 3 heterozygous for FII A20210, 
and 1 protein S deficiency). Features of thrombophilic and nonthrombophilic women are 
shown in Table 1. Among the women with thrombophilia, 4 (66.6%) showed an adverse 
obstetric outcome (1 intrauterine fetal death, 2 small-for-gestational age newborns with a 
weight below the fifth percentile, 1 severe preeclampsia). Among the nonthrombophilic 
women (n =35), 9 (25.7%) showed an adverse outcome (6 small-for-gestational age 
newborns, 3 intrauterine fetal deaths), with an odds ratio of 5.8 (95% confidence interval: 
0.9 –37.4). A recent study evaluated the presence of an association between common 
prothrombotic factors and increased blood flow resistance in the fetomaternal circulation, 
in addition to the occurrence of obstetric complications (2) The investigators did not find 
an association between thrombophilia and blood flow in the fetomaternal circulation in 
nulliparous women. The design of our study is different from that of Salomon and 
colleagues (2), and we believe that comparison between data is difficult when different 
study designs are used. We did not study only nulliparous women, although 68.3% of 
women (n= 28) were at their first pregnancy. Moreover, we decided to not evaluate the 
prevalence of the MTHFR 677TT homozygosity, as data about its role as a thrombophilic 
risk factor are not consistent. 
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TABLE 1 
Features of thrombophilic and nonthrombophilic women 
 
Feature Thrombophilic women (n= 6 Nonthrombophilic women (n= 35) 
Age (mean ± SD) 
Parity 
Gravidity 
 Smoked during pregnancy 
29.6 ± 5.5 
0.3 ±  0.8 
0.5 ±  1.2 
0 
29.3 ± 5.3 
0.5 ±  0.7 
1.5 ±  0.7 
7 a 
 
a All smoked 1–10 cigarettes/day 
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 PLACENTA, THROMBOPHYLIA and HIGH RISK PREGNANCY 
 
The link between  thrombophilia and adverse outcome of the pregnancy was well known 
in literature; we present a case of a patient with Protein C deficiency  and Budd Chiari 
syndrome. 
App. 6 
 
We report after  the management of the thrombophilia in pregnancy considering our 
experience and the experience of international literature. 
App. 7 
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App.6  
 
Pregnancy in a woman with a history of Budd-Chiari syndrome treated by porto-systemic 
shunt, protein C deficiency and bicornuate uterus                                    
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App. 7 Congress Preclampsia 2005 
 
Management of thrombophylia in pregnancy 
 
During pregnancy the risk of thrombosis is high. Thrombophilias are broadly defined as 
conditions predisposing to thrombosis with incremento of development of gestational 
vascular comlications such as first- and second trimester miscarriages, intrauterine 
growth restriction (IUGR), intrauterine fetal death, placental abruption, preclampsia. 
Many studies show a direct association beetwen thrombophilia and pregnancy 
complications; for this reason the management of women with a profile of thrombophilia 
must be more accurate. The complications of pregnancy after thrombosis are the major 
cause of perinatal and maternal morbidity and mortality worldwide with high social and 
economic impact. Preconceptional counselling, familiar history and preventive 
treatments, including low-molecular weight heparins, aspirine, folate are considerating in 
pregnancy and in puerperium. It will be necessary with accurate screening to value the 
presence of factor of thrombophilia and to choose with the patient the therapy 
considering collateral effects. Even if there are not prospective trials which quantified the 
risk of obstetric complications  in women with thrombophilia, preliminar datas suggest 
that the prophylaxis of coagulation may ameliorate outcome in women with 
thrombophilia. Multidisciplinar approach is another foundamental question. We analyse  
aspetcs of the queston considerino the modern literature. 
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Discussion 
Thrombophilia is a common factor risk with a prevalence of 15-25% in white population; 
the term thrombophilias encompasses both inherited and acquired conditions, continuos 
or transient with high risk of thrombosis; thrombophilias have particolar relevance in 
pregnancy due to the coexisting physiological alterations in the coagulation system that 
occur during pregnancy and which result in an increased tendency toward thrombosis. 
(Tab. I) These disorders increase the risk of thrombosis during pregnancy with risk of 
vascular complications.Risk of thrombosis is major of 5-6 fold during pregnancy, with 
same frequency in the three trimester of pregnancy and  3-10 fold major in post-partum. 
Thrombophilias is present in 50% of women with thrombosis correlated to the pregnancy. 
Sometimes the discovery of thrombophilic state occur in pregnancy. Placental 
pathological findings in women with thrombophilia are hallmarked by thrombosis and 
fibrin deposition with reduction od placental flow. Obstetric major complications as fetal 
loss, IUGR, preclampsia, abrupto occurr in 1-5% of women. (1-2) 
Hemostasis is regulated by a delicate equilibrium between factor procoagulant and factor 
anticoagulant. Alterations of any type may alter this equilibrim predisposing to 
thrombosis. Also in placenta there is this equilibrium; the slow placental flow and the 
high coagulation state during pregnancy with stasis that occur in area of poor perfusion 
may predispose to thrombosis and obstetrical complications. Even if the knowledges on 
therapy during pregnancy are poor, datas in literature suggest that some groups (women 
with personal or familiar history  of thromboebolic disease) will be screened for 
thrombophilia. Test are necessary  (Tab. II) also in women with history of fetal loss in 
first trimester, sever preclampsia, intrauterine growth retardation IUGR, abruption 
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placenta, intra uterine fetal deathm because always more knowledge show assocciation 
with thrombophilic factors. (Tab. III) 
 
 
Tab I. Prevalence of inherited and acquired thrombophilic disorders (1) 
Type Defect %  General 
Population  
% Patients 
1° TVP 
Risk TVP 
(OR) 
Inherited 
 -AT III 
- protein C deficiency 
- protein S  deficiency 
- Factor V Leiden (Etero) 
- Factor V Leiden (Omo) 
- Prothrombin gene mutation 
- hyperhomocysteinaemia 
- Methylenetetrahydrofolate reductasi 
mutation 
Acquired 
 - Antiphospholipid syndrome 
 
- Activate Proteina C resistance (without  
FV Leiden) 
 
Reduction of inactivation of thrombin  
Reduction of inactivation FVa , FVIIIa 
Reduction of inactivation FVa , FVIIIa 
Reductionof inactivation FVa Protein C attiv 
Reduction of inactivation FVa Proteina C attiv 
High levels of thrombin and prothrombin 
Endothelial disease 
Reduction of metilation of omocysteinaemia 
 
 
Alterated pathway Protein C, Annessina V loss, 
endothelial procoagulant effects 
Reduction of anticoagulant activity 
 
 
0,07 
0,3 
0,2 
5-8 
0,06 
3 
5 
10-20 
 
 
2 
 
8-11 
 
1 
3 
3 
20 
1,5 
6 
10 
11-12 
 
 
10-15 
 
24 
 
10-20 
6-8 
2-6 
4-8 
80 
2-4 
2-3 
0,7-2 
 
 
9 
 
2-4 
 
Tab. II Evaluation of laboratoristic risk factors of thrombosis (3) 
Test 1 level 
Evaluaion of protein  C activate resi stance or analysis of  DNA of  Factor  V 
Analysis DNA for mutation of protrhombin gene 
Omocysteinemia levels 
Lupus anticoagulant 
Antibody anticardiolina 
Emocrome  
Test II Level 
Functional evaluation of AT III 
Functional evaluation of protein C 
Functional evaluation of  protein S 
Test  III level 
Levels of fibrinogeno 
Levels of  Factor VIII 
Time of trhombin 
Reptilase time 
Test IV level 
Analyss of DNA for mutation C677T of MTHFR 
Levels of   factors V, VII, IX, X, XI 
Levels of trombomodulina 
Levels of tissutal activator of  plasminogeno 
Levels of di heparin cofactor II 
Major patients will be know with I and II level test; the III level test in the cases of familiar thrombosis when other test 
aren’t useful for diagnosis. The IV level test are utilized for research. 
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 Placental vascular complications associated with thrombophilia Tab. III (12) 
 Miscarriage IUFD Preclampsia Placental abruption 
Deficit Antitrombina III 
Deficit Proteina C 
Deficit Proteina S 
Disfibrinogenemia 
protein C Resistance   
Factor V Leiden 
MTHFR677TT 
Iperomocysteinemia 
Factor II G20210A 
Antiphospholipid syndrome 
 
Combined defects 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ 
+ 
+ 
+ + 
+ + 
+ + 
+ + 
+ + 
+ 
+ + 
+ + 
+ 
+ 
+ 
+ + 
+ + 
+ 
+ 
+ 
 
+ + 
+ + 
+ 
+ + 
+ 
+ + 
+ + 
 
+ 
+ 
 
+ 
+ + 
+ 
+ + 
+ + 
+ + 
+ + 
+ = Possible association  ++ = Association sure 
 
In many women with inherited trombophilia the pregnancy will finish without 
complications even if the risk of obstetrical disease will be elevated. The real motive 
becase only in some patient will occurr the obstetrical disease is unknown, even if we 
think and the literature too, that many other factors sistemic or local and placental play a 
foundamental role. 
The presence of more thrombophilic factors increase the thrombotic risk of 14 fold versus 
a single factor which increase the risk of 4-fold. (1) 
Actually 30-50% of vascular diseases of pregnancy are linked to the thrombophilia. 
We must discover if new factors thrombophilic congenital or acquired may play a role 
(trhombomodulin, gene of endothelial receptor of  protein C, deficit of factor XII, deficit 
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of protein Z, cofactor of the  X activated, high levels of procoagulant  microparticell) (1).    
For this motive the decision is to not include all patients in the screening for 
thrombophilia,, because the real benefits of this choose aren’t supported from this politic.  
(4). The presence of inherited thrombophilia, didn’t change the dose of therapy because 
the deficience of AT, protein C and protein S, the factor V Leiden and the mutation of  
protrhombin aren’t resistant to the anticoagulant therapy. 
The presence of this thrombophilic factors may change, increasing the time of 
administration, especially after one evnt of thrombosis. The optimal time of therapy 
depend from a balance between risk of thrombosis without therapy and risk of 
haemorrhage during the administration of anticoagulant; the therapy must be accuarate 
for each patient. (5)  
Women with history of thrombotic accident, generally are in therapy with dicumarolo 
inhibitor of vitamin K, with effect  teratogen well known; during the preconceptional 
must be outlined the importance of stop the therapy when there is a positive test of 
pregnancy; at the same time must be outlined the importance of start a therapy with low 
molecular weight heparin (LMWH) or fractionated heparin. 
Thromboembolism venous and pulmonary embolia are rare but serious complication 
during the pregnancy and are the principle cause of morbility and mortality in Europe  
and in USA. The number of deaths for million of pregnancy is changed in the last  20 
years.  In any case the incidence of thromboembolic venous disease is  0,5-0,7 / 1000 
delivery while the incidence of pulmonary embolia is 1/2500- 1/10000 (in the case of 
caesarean delivery the risk show an increase of 3-fold) 6). 
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The thrombotic events are the same in pregnancy and in post-partum with a distribution 
in the three trimester. The major incidence of death will be occurr in the first two weeks 
after delivery and the 40% 2-6 weeks after the delivery, so after dimission.  The risk 
factors for  TEV are numerous and would evaluate in all pregnancies.  (Tab. IV).  
 
 
Risk factors for thromboembolism in pregnacy and in puerperium (Tab. IV) RCOG 2004 
(30) 
Preesistent                                                                                                                 New or transient 
Precedent history of thromboembolism                                                       Surgery in pregnancy or puerperium 
Trhombophilia                                                                                                         Operative delivery 
-inherited: Deficit AT III, Deficit Protein C/Protein S,                                         Immobility > 4 days 
Fattore V Leiden, variant prothrombin                                                                  Disidratation state  
- acquired: Antiphospholipid syndrome, lupus anticoagulant                                Haeemorrage 
Ab anti cardiolipina                                                                                                Iperemesi 
Age > 35 anni                                                                                                       Ovarian hyperstimulation syndrome  
(BMI > 30 Kg/ m2)                                                                                               Pre-eclampsia 
Parity > 4                                                                                                              Long labour 
varicous disease 
Paraplegia  
sickle cell disease Infections 
Mieloproliferative diseases  
 
 
For the thrombophilia and Antiphospholipid syndrome there is a grade of risk that change 
considerino the defects; the anomalies with high risk are: deficience of  AT III (30%), 
omozigous for Factor V Leiden, the positivity for antibody antiphospholipid  and the 
presence of combined antibody. For the prevention of the thromboembolic disease is 
foundamental the evaluation of therapy with anticoagulation and the possible diagnostic 
deeper. 
In the cases of thromboembolic events  (Familiar < 40 yearsi) before the concepeption 
will be useful the screening for inherited or acquired thrombophilia, to limit the periods 
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of immobility and the state of disistration. In the presence of  signs suggestive of 
antiphospholipid syndrome (trhombosis arterious/venous, miscarriage, thrombocitopenia) 
other tests as the research of Lupus anticoagulant and antibody anti cardiolipin are useful. 
The women with history of venous thromboembolism received ENF (50-100 u/kg in bolo 
follone from1250-1500U/h in continuos infusion (aPTT ratio= 1,5-2) for 5-10 days  
followed from ENF every 12 h s.c. with dose accurate (aPTT ratio 1.5-2.5 a 6 h from 
each administration) to term and for 6 weeks in post-partum. Today a good alternative is  
of heparin  LMWH 80-100 U/Kg every  12h in first phase and after 50-80 U/kg every 
12h successively. For the ENF the dose will be reduced to 5000-7500 UI sc every 12h 
when the labour start or before the caesarean delivery. For the low molecular weight 
heparin it is necessary to stop  the administration to the start of labour or 12 hours before 
cesarea delivery. Therapy must be stop 24h before induction of delivery; it is considered 
sure to stop the therapy in immediate pre-partum and postpartum. 
Therapy may after restarted in EV (2000UI in bolo follone from 1200 UI/h in continuos 
infusion) or in s.c. and it may continue until restarted of oral therapy. 
Women with positive history for thromboembolic event have a risk of recidive of 4-15%; 
in these women the optimal plasmatic levels of heparin are  0,08 - 0,15 UI/ml (median 
dose 16400 UI/die) (7). 
Potential advantage of LMWH heparin on  ENF are the major antithrombothic action, a 
minor risk of haemorrhage a single injection for emilife more long, minor dose of the 
heparin, minor thrombocitopenia, minor risk of osteoporosis. (10) A collaborative study 
of the 1998 showed the safety and the success of heparin LMWH  90% of women with a 
history of recurrent pregnancy loss and in 100% of women with preclampsia in the 
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precedent pregnancy. (11) The administration of Enoxaparin 20mg/die showed a good 
success until 80% of live birth in patient with a history of recurrent miscarriage (12). The 
administration of Enoxaparin 40mg/die showed a success of 75%  of live birth at term in 
a group of patients with history of thrombophilia versus only 20% in pregnancies of the 
same group in women withot therapy 
This success was observed also in other studies not randomized. (Tab. V) (13-14)  
 
 
 
 
 
 
 
Observational studies for prevention of poor prognosis of pregnancy in women with thrombophilic diseases (Tab. V) 
(13-14, 27) 
 N° women Defect history Therapy Alve born 
 
- Brenner 2000 
 
 
- Grandone 2002 
 
- Kupferminc 2001  
 
- Riyazi 1998 
 
 
- Younis 2000 
 
- Carp, 2003 
 
 
50 
 
 
25 
 
33 
 
26 vs 19  
 
 
7 
 
37 vs 48 
 
Congenital/acquired 
 
FV o FII 
 
 
Not specified  
 
Congenital or acquired
 
 
Factor V Leiden 
 
Congenital 
 
RPL 
 
 
RPL; IUGR; PE 
 
Obstetrical 
complication 
Obstetrical 
complication 
 
RPL ricurrent 
 
RPL 
 
Enoxaparin /ASA 
 
 
UFH/LMWH/ASA 
 
Enoxaparin 40mg + ASA 
 
Enoxaparin 40 mg + ASA 
 
 
Enoxaparin 40 mg + ASA 
 
Enoxaparin 40 mg 
 
 
46/61 
 
 
29/31 
 
30/33 
 
Peso > 
 
 
5/7 
 
70% vs 
40% 
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ENF was the drug of choose for the prophilaxys and the therapy of venous  
thromboembolism in pregnancy; this drug do not cross the placenta with no potential 
teratogenesis or haemorrhage for the fetus. (15)  
Maternal complications reported during the therapy have an incidence of 3% 
(osteoporosis, thrombocitopenia, allergic disease and  haemorrhage (16). 
Low molecular weight heparin are sure for the fetus because do not cross the placenta 
and have a efficient and safety comparable with the heparin ENF. 
Data on the more accurate dose are not disponibile, and we choose the dose on the basis 
of the weight. In high risk pregnancy for thrombotic event a possible solution was to 
utilize a dose of Dalteparin 5000 UI every 24h in women with weight < 100 Kg and 
5000UI  every 12h in women with weight > 100 Kg. The rate of complications  (vertebral 
rupture for osteoporosis) is the same of the heparin ENF (2,2%). (17)  
A metanalysis of Sanson on the safety of low molecular weight heparin LMWH in 
pregnancy report an incidence of poor out come in the patients with associated diseases 
of 13% eand only 3% in patient without diseases. (18)  If we consider the haemorrhagic 
complications of the patients that utilize heparin LMWH versus the patient that do not 
utilize this therapy, it was observed a major risk of haemorrhage during delivery and 
major incidence of anemia (19) 
Protamina sulfate was the drug contrasting heparin when haemorrhage starts ( the dose is 
1 mg every 100 UI; for the nadroparin it is necessary half dose. 
Oral anticoagulant may cross placenta causing teratogenesis (skeletal dysplasia, nasal 
hypoplasia). Incidence of 5-10% between  6a 12a week of gestation. For many authors 
the risk of miscarriage is high in contrasto f the patient that didn’t receive heparin. (20) 
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Other malformations reported are malformation of SNC and of the eyes. The risk of 
teratogenesis is probable for the high dose of druf; some data show that a dose <5 mg 
may be sure. These datas must been confirmed.  (21) As this drug do not cross in the milk 
it may start again in puerperium. Aspirin is a sure drug when used pregnancy in low dose 
(50-150 mg). There is no study showing a significantly difference versus placebo in 
incidence of preclampsia, preterm delivery or intrauterine death. (22-23) 
We must again estabilish if the asa has a role as the heparin. The prevalence of 
thrombophilia, placental tissutal deposition of fybrina, risk of recurrence are a good 
reason for the start of trials on the prophilaxys with anticoagulant for ameliorate out come 
of women with thrombophilic state and fetal loss recurrent. To support this hypotesis the 
better outcome of women with Antiphospholipid syndrome  receiving antithrombotic 
therapy; the rate of live birth is major in women receiving heparin plus asa (80%) in 
confronto of women receiving only aspirin (40%) (24-25) Women with thrombophilic 
state and obstetrical diseases showed better Doppler flow of the uterine arteries in the 
next pregnancies after therapy with enoxaparina and aspirin. (26) We report some 
guidelines. 
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Tab.VI Guidelines for prevention of  thromboembolism and use of heparin in pregnancy 
(7, 8, 30) 
SISET (2002) ACCP (2004) RCOG (2004) 
a) Low-moderate risk: control 
clinic/strumental, 
elastocompression, fast mobility 
 
b) High risk no thrombophilia: 
LMWH 2000-5000 UI/die sc last 
weeks and puerperium + a) 
 
c) High risk + thrombophilia: 
LMWH 2000-5000 UI/die sc 
during pregnancy considerino the 
weight + a) + b)  
a) TVP + transient risk: look and 
prophylaxis (LMWH) postpartum 
 
b) TVP + thrombophilia or  
familiarity: prophylaxis 
antepartum and postpartum 
(LMWH) 
 
c) Numeroseous TVP prophylaxisi 
antepartum + major period of 
postpartum (LMWH) 
 
d) Antiphospholipid syndrome 
LMWH + ASA 
a) Precedent TVP no 
trhombophilia LMWH only post 
partum. Antepartum if TVP 
recurrent, risk factors no 
transienti, familiarità for  TVP 
 
b) Precedent TVP + 
thrombophilia LMWH 
antepartum and post-partum 
 
c) thrombophilia without TVP 
prophyilaxis antepartum and/or 
postpartum considerino risk 
factors  
d) women with  4 or more risk 
factors eventually antepartum e 3-
5 days postpartum LMWH 
 
In puerperium we must continue with  LMWH or oral anticoagulant. The prophilaxys for 
women at risk is not well estabilished for the insufficient evidences and for the data of 
expert opinion and no trilals. 
Even if the few trials compare the prophylaxis with placebo or 2 methods of prophilaxys, 
it is hard to estabilish if the therapy is efficient because low number of patients. (9)  
Optimal dose of low molecular weight heparin must again be estabilish; new trials are 
becessary. 
 Therapy indicated from RCOG (Tab. VII) 
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Tab. VII Prenatal prophilaxis and therapy with LMWH.  RCOG 2004 (30) 
Prophylaxis Enoxaparin (100U/mg) Dalteparin Tinzaparin 
Normal weight (50-90Kg) 
Weight < 50 Kg 
Weight > 90 KG 
Major dose 
Therapeutic dose 
40 mg/die 
20 mg/die 
40mg/12h 
40mg/12h 
1mg/kg 12h 
5000 U/die 
2500 U/die 
5000 U/12h 
5000 U/12h 
90 U/Kg 12h 
4500 U/die 
3500 U/die 
4500 U/12h 
4500 U/12h 
90U/kg 12h 
 
Randomized multicentric controller trials will compare two dasage of  enoxaparin in 
women with recurrent fetal loss. Therapy with 40 mg and dose with 80mg are equally  
efficacious with live birth of 81% and  77% compared with only 28% in precedent 
pregnancies. 
Incidence of preclampsia and abruption placenta are more low. (27-28) In any case aren’t 
accurate trials showing the real efficacy of heparin on the out come of pregnancy in 
women with thrombophilia. (29)  
A trial placebo-controls evaluating the real benefits of heparin is ethically wrong and 
impossible.  
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APOPTOSIS and PRECLAMPSIA 
 
Pregnancy complications such as preeclampsia, intrauterine growth retardation (IUGR) 
preterm labor affect a considerable number of pregnancies and account for significant 
perinatal morbidity and mortality. Although the pathophysiology has not been clearly 
defined, the common phenomenon observed between these diseases is abnormal 
development and function of the placenta (1–2). Normal placental development is 
dependent upon the differentiation and invasion of the trophoblast, the main cellular 
component of the placenta that originates from the trophoectoderm of the blastocyst early 
in pregnancy. During this process of differentiation and invasion, trophoblast cells 
rapidly divide to form the interface between mother and embryo, while other trophoblast 
subpopulations invade the decidua (pregnant endometrium) to remodel the arterial blood 
vessels in the uterine wall, known as the spiral arteries, to accommodate the expansion of 
extraembryonic tissue and to increase blood flow to the placenta and developing fetus. As 
a developing organ, the placenta undergoes constant. Tissue remodeling, which is 
characterized by the functional loss of trophoblast cells by apoptosis.  
Apoptosis, or programmed cell death, is an active process by which superfluous or 
dysfunctional cells are eliminated to maintain normal tissue function. Depending on the 
stimuli, apoptosis may be initiated by one of two known pathways: intrinsically by the 
mitochondrial pathway and extrinsically by either the death receptor-mediated pathway 
or in response to exogenous stimuli such as cytokines (Fig.1). The central executioners of 
apoptosis are the caspases, which area family of cysteine proteases that cleave numerous 
vital cellular proteins to affect the apoptotic cascade. Several endogenous inhibitors, 
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including flice-like inhibitory proteins(FLIPs), inhibitors of apoptosis (IAPs), and 
antiapoptoticBcl-2 family members, inhibit caspase activation, there by preventing 
further propagation of the death signal. Whereas apoptosis is thought to be important for 
normal placental development, it may also be involved in the pathological conditions 
associated with this organ. Apoptotic cell shave been identified in both the maternal and 
fetal compartments of the placenta during normal pregnancy, and the presence of these 
cells may be related to the stage of placental development, including the attachment and 
invasion of the trophoblast (3), spiral artery transformation, trophoblast differentiation 
and turnover, and parturition (4). In complicated pregnancies such as preeclampsia or 
IUGR, a greater incidence of trophoblast apoptosis has been observed(5-9), suggesting 
that alterations in the regulation of trophoblast apoptosis may contribute to the 
pathophysiology of these diseases. 
In placentas from complicated pregnancies, shallow trophoblast invasion and inefficient 
spiral artery transformation have been observed (10-11), which may be partly due to the 
distribution and activation state of infiltrating macrophages 
 
 
 
 
 
 
 
 
 125
  
Fig.1 Two known pathways of apoptosis: intrinsically by the mitochondrial pathway and 
extrinsically by either the death receptor-mediated pathway or in response to exogenous 
stimuli. 
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We evaluate morphogenetic alterations of placenta and apoptosis of trophoblast into 
placenta of pregnancies with preeclampsia/intrauterine growth restriction and controls. 
 
App. 8 
Morphogenetic alterations and apoptosis in placenta from 
pregnancies complicated by preeclampsia /intrauterine growth 
restriction: role of HGF/c-met/STAT3 and bcl-2. 
 
Objective: Impaired trophoblast invasion is associated with early-onset Preeclampsia and 
intrauterine growth restriction. We evaluate morphogenetic alterations of placenta and 
apoptosis of trophoblast into placenta of pregnancies with preeclampsia/intrauterine 
growth restriction and controls. 
Study design: Pacental section were obtained from women with early-onset 
preeclampsia/intrauterine growth restriction (n 11) and in controls (n18). Trophoblast’s  
apoptosis into placenta was quantified evaluating bcl-2 apoptosis marker . Placental’s 
morphogenetic alterations was evaluated with HGF/c-met/STAT3 cascade. 
Results: Trophoblast apoptosis was not increased in  preeclampsia/intrauterine growth 
restriction significantly (P>0,05); HGF/c-met/STAT3 cascade was completely altered in 
severe IUGR patients with placentas showing absence of  peripheral ramifications 
(P<0,05). 
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Conclusion: This review focuses on the role of trophoblast apoptosis into placenta and 
show the role of  HGF/c-met/STAT3 cascade in the onset of pregnancies with 
preeclampsia/intrauterine growth restriction. 
 
 
Introduction 
 
Preeclampsia is a potentially fatal complication of human pregnancy characterized by 
hypertension, proteinuria and edema. This disease complicates 5 to 10% of pregnancies 
and is a leading cause of maternal and fetal mortality and morbidity. (1) Intrauterine 
growth restriction defined as birth weight </=5th percentile or </=10th percentile for 
gestational age is a frequent cause of perinatal morbidity (2) and it may be a complication 
of hypertensive disorders such as preeclampsia . Although the cause of these diseases are 
unknown, inadequate invasion and remodelling of maternal uterine arteries by 
extravillous trophoblasts (EVTs) in the first trimester are a common feature. (3) 
Apoptosis, or programmed cell death, is an active process by which superfluous or 
dysfunctional cells are eliminated to maintain normal tissue function; this process is 
important for normal placental development, but it may also be involved in the 
pathophysiology of pregnancy-related diseases. Normal placental development is 
dependent upon the differentiation and invasion of the trophoblast, the main cellular 
component of the placenta. Trophoblast apoptosis increases in normal placentas as 
gestation proceeds but a greater incidence of trophoblast apoptosis has been observed in 
pregnancies complicated by preeclampsia or intrauterine growth retardation (IUGR).(4) 
The central executioners of apoptosis are the caspases, which cleave numerous vital 
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cellular proteins to affect the apoptotic cascade. By inhibiting caspase activation, several 
endogenous inhibitors, including the antiapoptotic Bcl-2 family members, can prevent 
further propagation of the death signal.  
Hepatocyte Growth Factor (HGF) and its receptor, c-met, are essential components of 
intercellular signaling pathways for the control of growth and differentiation. This factor 
functions as mitogen, and morphogen for a variety of cultured cells and increases the 
invasiveness of epithelial cells. The human placenta is one of the original sources from 
which HGF was purified to homogeneity and the factor is now generally considered to be 
critical for placental growth and organogenesis. (5) 
The etiology of preeclampsia is poorly understood; however, one characteristic of this 
disease is a lack of trophoblast invasion into the maternal decidual arteries; this decrease 
in arterial trophoblast invasion is thought to result in placental hypoxemia with 
subsequent production of  placental factors that lead to the development of preeclampsia 
(6). Although the mechanism for decreased trophoblast invasion in preeclampsia is 
unknown, abnormal trophoblast integrin expression, insulin-like growth factors, and 
hypoxia have all been implicated in this process (7). In addition, a number of other 
cytokines, including transforming growth facot-b, epidermal growth factor, and 
interleukin-1, have been shown to regulate trophoblast invasion in vitro. (8)Another 
cytokine that may  affect trophoblast invasion is hepatocyte growth factor (HGF) (9) 
We hypothesized a concomitant role of  an anomalous apoptosis process and the 
alteration of the HGF/c-met/STAT3 cascade with an anomalous placental morphology in 
the develop of the preeclampsia and IUGR. A different grade of  apoptosis was observed 
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in the patient with pregnancies complicated by preeclampsia and intrauterine growth 
retardation (IUGR) . 
 
 
Material and methods  
 
Placental tissues of gestation (n°29) were obtained by  elective cesarean or spontaneous 
vaginal delivery from uncomplicated subjects (n° 18) and from patients with 
preeclampsia (n°3) and or with pregnancy complicated by intra uterine growth 
retardation(n°8). Uncomplicated subjects were normotensive throughout pregnancy and 
had no proteinuria or other signs of preeclampsia. Although these subjects included 
women undergoing spontaneous preterm labor, the cases with  clinical chorioamnionitis 
(fever, maternal or fetal tachycardia, uterine tenderness, foul odor, and leukocytosis) 
were excluded. The gestational weeks of  preeclamptic pregnancies ranged from 26-39 
weeks. The gestational ages of all cases were determined by ultrasonographic 
examination in the first trimester. The mean birth weight in preeclamptic pregnancies was 
1411.8 ± 811 g. Preclampsia was established for systolic and diastolic blood pressure 
above 140 mm Hg and 90 mm Hg, on at least two occasions 6 or more hours apart, 
together with generalized edema or proteinuria. Proteinuria was defined as 300 mg or 
more. 
 
Discussion 
The human placenta is composed of  mononuclear cells, cytotrophoblasts, which coalesce 
to become a multinucleated syncytium. Maintenance of trophoblast structure and 
differentiated function is essential for the provision of adequate gas, nutrient, and waste 
 132
exchange between the fetus and the mother. Placental trophoblasts may be subject to 
diverse insults during normal human pregnancy. Clinical conditions such as 
preeclampsia, anemia, smoking, and living in a high altitude can lead to placental 
underperfusion and villous hypoxia, characterized by diminished syncytial 
differentiation, syncytial knots, and prominent cytotrophoblasts. During the process of 
differentiation and invasion, trophoblast cells rapidly divide to form the interface between 
mother and embryo, while other trophoblast subpopulations invade the decidua (pregnant 
endometrium) to remodel the arterial blood vessels in the uterine wall, known as the 
spiral arteries, to accommodate the expansion of extraembryonic tissue and to increase 
blood flow to the placenta and developing fetus. 
As a developing organ, the placenta undergoes constant tissue remodelling, which is 
characterized by the functional loss of trophoblast cells by apoptosis. After proliferation 
and differentiation into specific cell subtypes, aging trophoblast cells are selectively 
removed and replaced by a younger population of trophoblasts without affecting 
neighboring cells (10) 
A greater incidence of villous as well as extravillous trophoblast apoptosis has been 
detected in placentas from pregnancies complicated by preeclampsia or IUGR, 
suggesting that the appropriate regulation of trophoblast apoptosis is important for 
normal pregnancy.  (11-14). In response to different stimuli, apoptosis may be initiated 
extrinsically by the death receptor pathway or intrinsically by the mitochondrial pathway. 
The central executioners of apoptosis are the caspases, which cleave numerous vital 
cellular proteins to affect the apoptotic cascade. By inhibiting caspase activation, several 
endogenous inhibitors, including flice-like inhibitory proteins (FLIPs), inhibitors of 
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apoptosis (IAPs), and antiapoptotic Bcl-2 family members, can prevent further 
propagation of the death signal. Macrophages present at the maternal-fetal interface may 
also contribute to trophoblast survival by removing apoptotic cells and producing 
cytokines and growth factors, which influence the progression of the apoptotic cascade. 
(4) 
Although some studies observed no differences in the expression of Bcl-2 in placental 
villi from complicated and normal pregnancies (15 ), a subsequent study reported that 
Bcl-2 expression was less abundant in syncytiotrophoblasts from severe preeclamptic and 
IUGR placentas than in the normal controls (16). Other authors demonstrated that the 
apoptotic extravillous cytotrophoblasts detected in preeclamptic samples were negative 
for Bcl-2 expression, suggesting that a decrease in Bcl-2 expression may induce 
apoptosis in extravillous trophoblast cells.  (14, 17) 
 
 
 
The group of patients with preclampsia showed a reduction of expression of the cascade 
HGF/c-met/Stat 3 with positive bcl-2 anti apoptosis markers. Placental morphology show 
a maturative stop in the process of throphoblast invasion. In the patients with IUGR, we 
observed villi with excessive ramification process and a soft reduction of the expression 
of the cascade. The bcl-2 markers was negative as expression of high grade of apoptosis. 
 
 
 
 134
 We were not able to find any report in a MEDLINE search from 1966 using the key 
words apoptosis, HGF, preeclampsia. 
Enhanced trophoblast apoptosis and anomalies of placental morphology  has been 
observed in the placentas of women with preeclampsia and/or intra-uterine growth 
retardation. 
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PLACENTA and FETAL MALFORMATION 
 
 
Many fetal malformations as the neural tube defects (NTD) are linked to morphogenetic 
alterations due to a defective development of the embrional phases. Hepatocyte growth 
factor (HGF)/c-met system plays a role in morphogenesis of nervous system, lung, and 
kidney. Hepatocyte growth factor, also called scatter factor (SF), is a multifunctional 
cytokine that promotes growth, differentiation, invasion, angiogenesis, and 
morphogenesis. HGF/c-met morphogenetic effects are mediated by signal transducers 
and activators of transcription (STAT)3 and both HGF and c-met genes are regulated 
from p53. A reduced mRNA expression of HGF/c-met/STAT3 pathway was found in the 
malformed nervous systems and placentas. On the contrary, detectable expression levels 
of p53, HGF, c-met, and STAT3 were observed in non-malformed fetus and in placenta 
of uncomplicated pregnancies. Many fetal malformation and pregnancy complicated with 
PE may be the linked for the presence of the same alteration of placental morphogenesis, 
with a reduction in all components of the p53/HGF/c-met/STAT3 cascade. (1) The 
placenta is a rich source of HGF/SF, and its absence in mice has been shown to lead to 
impaired placental growth and embryonic death (2)  
A possible relationship between hepatocyte growth factor (HGF) expression and the 
pathogenesis of preeclampsia was evaluate in some studies; Furugori et al. measured the 
concentration of immunoreactive HGF and the expression of HGF messenger ribonucleic 
acid (mRNA) in human placentas obtained from two groups: uncomplicated and 
preeclamptic pregnancies at various gestational weeks. In addition, the localization of 
HGF mRNA and c-met protein was analyzed using in situ hybridization and 
 138
immunohistochemical staining, respectively. The expression of HGF mRNA and the 
concentration of immunoreactive HGF were highest in second trimester and were 
significantly decreased in preeclamptic placentas compared with the uncomplicated cases 
in third trimester. These results provide evidence of an abnormality of HGF expression in 
the preeclamptic placentas. Such placentas exhibit the abnormally shallow trophoblast 
invasion of the uterus, and reduced expression of HGF could well account for 
this morphometric change. (3) Hepatocyte growth factor (HGF) is a cytokine that is 
produced in  the placental villous core and acts in a paracrine manner on trophoblasts that 
express the HGF receptor Met. Because HGF stimulates the invasion of many epithelial 
cell types, villous core HGF could regulate placental trophoblast invasion. As 
preeclampsia is characterized by inadequate trophoblast invasion, Kauma et al 
investigated the hypothesis that decreased placental HGF production is a mechanism for 
inadequate trophoblast invasion in this disease. Placental villous explant HGF production 
over 24 h was 25% lower in patients with preeclampsia than in normal These studies 
suggest that HGF has an important role in placental trophoblast invasion. In addition, 
decreased placental production of HGF in preeclampsia provides a potential mechanism 
for the lack of trophoblast invasion that is seen in this pregnancy disorder. (4) 
Prenatally diagnosed malformation or anomalies of karyotipe as trisomy 16 mosaicism 
are associated with the increased risk of poor pregnancy outcome including intrauterine 
growth restriction, intrauterine death and fetal malformation. While maternal 
preeclampsia has also been reported in some cases, this has not been systematically 
evaluated. To better define the risk of preeclampsia and the clinical course of 
preeclampsia in these pregnancies and to identify associated clinical variables, a study 
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reviewed 25 cases of prenatally diagnosed trisomy 16 mosaicism for which molecular 
studies were undertaken and sufficient obstetrical data were present to include/exclude 
the diagnosis of preeclampsia. Six of 25 (24%) mosaic trisomy 16 cases exhibited 
preeclampsia as compared to 3 of 44 (7%) matched controls. There were no differences 
between those mosaic trisomy 16 cases presenting with preeclampsia and those that did 
not, in terms of the presence/absence of UPD, IUGR, malformation, or trisomy on 
amniocentesis. The levels of trisomy tended to be high in placentas associated with 
preeclampsia; however very high levels of placental trisomy were also often seen in the 
absence of preeclampsiaAs it is impossible to predict which subset of cases is at highest 
risk, all women receiving a prenatal diagnosis of trisomy 16 mosaicism should be closely 
monitored for signs of preeclampsia. (5) 
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We have evaluated several placentas obtained immediately after delivery from normal 
(n°= 18), preeclamptic  pregnancies (n°=11) (29–40 weeks gestation) and placentas of 
pregnancies complicated with fetal malformation. Immediately after obtaining the 
placenta, placental villi were dissected free from the decidua basalis, minced into small 
pieces, and rinsed free of blood. The placental villi (350 mg wet weight) were 
cultured in duplicate in 5 mL DMEM with 10 mmol l-glutamine, 100 mIU/mL penicillin, 
and 100 mg/mL streptomycin, pH 7.4 (Sigma Chemical Co., St. Louis, MO) for 24 h, and 
the medium was stored at -20 C until assayed for HGF. HGF in placental villous explant-
conditioned medium was quantified by a sandwich ELISA for human HGF. We now are 
analyzing the dates from the placenta. Some of the cases of fetal malformation, for the 
particularity of the clinical features and the precocity of prenatal ultrasound diagnosis 
were reported.  
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 App. 13 
Prenatal Diagnosis of placental chorioangioma: our experience. 
Minerva Ginecol. 2005 Dec; 57 (6) 649-654 
 
 
ABSTRACT 
Placental chorioangioma is the most common benign tumor of placenta. The relationship 
of vascularized chorioangiomas to adverse pregnancy outcome is well recognized. We 
report three cases of placental chorioangioma. Hypervascularization of the lesions in all 
patients and the immune hydrops with adverse fetal outcome in two cases are the 
complications of the our mini-series. The ultrasonography and Doppler ultrasonography 
findings were useful in establishing the prenatal diagnosis and the prognosis. 
 
INTRODUCTION 
 
Placental chorioangioma is the most common benign tumor of placenta, encountered in 
approximately 1% of all pregnancies; probably its origin is hamartomatous. In the cases 
of  prevalent  mixomatous component chorioangioma will appear ipoechogenic and 
negative to the Color-Doppler; in the cases of  prevalent vascular component 
chorioangioma will appear ipoechogenic and positive to the Color-Doppler. Congestive 
heart failure could be determinated because  two possible reasons: 1) intralesional mass 
circulating sequestration, usually associated with tumors greater than 5 cm in diameter; 2) 
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tumor’s compression on the umbilical cord, when chorioangioma is located near the 
placental hilus. Cardio-circulating failure, if present, will appeare with the hydrops 
features (1,2,3,4). Other possible complications could be: polyhydramnios, preterm birth, 
fetal anemia, growth retardation (I.U.G.R), fetal anemia, intrauterine fetal death (1,2,3,4).  
 
CASE 1 
 
A 32-year-old-caucasian woman, II Gravida I Para, was referred to our unit at 18 weeks 
of gestation. Ultrasonography examination revealed a biamniotic bichorial twin 
pregnancy. An hyperechogenic area of 41 mm positive to the Color-Doppler, was 
observed in the placenta of one of the two twins (female twin). This  lesion was 
contiguous to the hilus but didn’t modify the umbilical cord Doppler’s values. Hydrops, 
ascitis or  cardiac failures were not observed. The placenta of the other twin appeared 
normal. Amniotic fluid  quantity was regular in  both of the amniotic sacs.  Both fetuses 
biometry and anatomy  were regular. Regular  fetal fluximetries were indicative of a 
normal feto-placental hemodynamic. After about 4 weeks the female twin developed 
congestive heart failure, hydrops and after two days she died .The other twin was 
delivered at term after caesarean section performed at 39weeks of gestation.The male 
baby weighed 3350 g , with Apgar scores 8 and 9at 1 and 5 minutes, respectively. 
 
CASE 2 
A 28-year-old-caucasian woman, I Gravida, came to our observation at 31 weeks of 
gestation. Fetal ultrasonography revealed a disomogeneous placental formation, high 
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positive to the Color-Doppler of approximately 71 x 57 mm. Placental hilus was distant 
to the lesion. Hydrops, ascitis or cardiac failures were not observed. Fetal anatomy and 
biometry were regular. Hearth Doppler velocimetry was regular. Amniotic fluid quantity 
and fetal fluximetries were regular. The patient was evaluated every week.A caesarean 
section was performed at 35weeks of gestation because the rapid increase of the 
chorioangioma’s biometry and the initial heart failure. The newborn weighed 3210 g, 
with Apgar scores 7 and 9 at 1 and 5 minutes, respectively.  
 
CASE 3 
A 27-year-caucasian woman, I Gravida, was referred to our unit at 24 weeks of gestation 
. The transabdominal ultrasound examination showed a vascularized  placental 
hypoechogenic formation. The biometry of the lesion was of 82 x 72 mm. A diffused 
subcutaneous hydrops, hydrotorax, cardiomegaly, hepatomegaly, polydramnios were 
present. These signs are secondary to the hearth failure because the presence of the 
chorioangioma. Fetal biometry was regular for the gestational age. Remaining fetal 
anatomy was normal. Amniotic fluid was increased with largest vertical pocket of 95mm 
(n.v. 20-80 mm) and AFI of 31 (n.v. 6-20). Uterine fluximetry was normal as in right 
trophoblastic invasion. Arterious fetal fluximetry was regular; venosous fetal fluximetry 
expressed cardiac failure. Fetal complications as polyhydramnios and cardio-circulating 
failure were responsible of intrauterine death at 30 weeks of gestation. The pathology 
report confirmed the prenatal diagnosis of  placental chorioangioma. 
 163
DISCUSSION 
 
Placental chorioangioma is the most common benign tumor of placenta, encountered in 
approximately 1% of all pregnancies. (1) Often the tumors have a microscopic volume. 
The incidence of chorioangiomas enough large to determine an alteration of the fetal 
cardio-circulating dynamic and which ultrasonographic diagnosis is possible, was 
approximately 1/8000- 1/50000 pregnancies  and 1/3500 to 1/9000  births (1,5,6,7). We 
know two types of chorioangioma: the angiomatous type with numerosous blood vessles 
and the mixomatous type with mesenchymal tissue and without hipervascularization (1). 
Large placental chorioangiomas have a variable shape and often protrude from the fetal 
surface of the placenta near the cord isertion; in these tumors were often observed 
ialinizations, calcifications, necrotic phenomenons (1).  The sonographic diagnosis is 
often occasional and it could be associated to an increase of the alfa-feto protein in the 
amniotic fluid and in the maternal serum. MRI could add clearness to the sonografic 
feature (9). Sonographic diagnosis is based on the detection of a circuscribed solid mass 
(hyperechogenic or hypoechogenic) or a complex mass. Most of the tumors are located 
near the cord placental insertion (1). Jauniaux et al propose that an high echogenicity of 
the angiomatosous lesion is associated to a better prognosis related with the fibrotic 
degeneration of the tumor (5). Some autors report case of spontaneous tumor infarction 
with a decreasing of the volume and the echogenicity (10); other autors didn’t found 
correlation between volume and echogenigity changes and the intramural tumor flux 
(11,12). The 3D-power doppler analysis showed a reduction of the vascular density after 
a spontaneous infarction of a big lesion without change of tipycal ultrasonography 
 164
features. This feature was probably determined by thrombotic degenerations as reported 
in the isthologic analysis. Tumor biometry is constant in the second half of pregnancy, 
even if in our experience there was a rapid increase of the tumors in the second half of 
pregnancy(case 2 and case 3). Obstetric complications of the chorioangiomas are: 
polyhydramnios (1,2,3,4),  preterm birth, fetal anemia, IUGR (1,2,3,4). The high 
incidence of the preterm birth is indipendent by tumor biometry; in all cases of preterm 
birth could be necessary a analysis of the  placenta (8).Polyhydramnios was reported in 
33% of the cases (1); its etiology was uncertain althogh most of the tumors are large and 
the high vascularization could cause a rise of amniotic fluid because transudation of 
liquid through the vessles’ wall (13). A correlation between polyhydramnios and preterm 
birth was also be reported a because the uterine over-distension (5). Amnioreduction was 
successful reported with a better neonatal outcome. Hearth failure and hydrops are 
complications of the tumor vascularization rather then its volume. This feature is evident 
in the Case 3. Other complications include toxemia, abruptio placentae, placenta previa 
(1). A good prognosis could be previewed when a large mass isn’t much vascularized (5). 
This date was also confirmed by other authors in the cases of fibrotic tumor’s 
degeneration . The in utero management and therapy by ablation or an alcohol injection 
were made with variable results (4,14). Other possible in utero approaches are the fetal 
transfusion, the tumor vesseles ligation (15) and the vesseles termocoagulation. An other 
intrauterine surgical treatment; is the microhembolization with an interstitial laser; this 
innovative technique was associated with a premature delivery even if the neonatal and 
maternal outcome were good (16).Differential diagnosis include hematomas (3) 
(chorionic and subamniotic hematomas), other placental masses (teratomas), partial 
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hydatidiform mole and maternal placental metastatic tumors (17,18).Frequently the 
chorioangioma is associated to the twin-pregnancies, the single umbilical artery and the 
velamentous cord insertion. 
The accurate study of placenta structure is a fundamental part of a ultrasonography exam 
in all the period of pregnancy; a prenatal ultrasonography diagnosis of the chorioangioma 
is possible in many case (4,8). The potential value of 3D power Doppler in prenatal 
diagnosis and monitoring of pregnancies complicated by large, vascularized 
chorioangioma was recently recognized.(12)The strict ultrasonography surveillance is 
necessary to prevent the unfavourable fetal outcome of the largest tumors as happened in 
the case 2; the tumor’s volume evaluation and the vascularization of the mass by Doppler 
are high useful to monitorize the possible fetal complications. The volume’s increase of 
the mass and the possible effects of the chorioangioma on feto-placental hemodynamic, 
fetal growth and amniotic fluid quantity are well recognized by ultrasonography. When 
the patient decline the fetal invasive therapy, whose complications are high again, the 
recognition of the ultrasonography features of an high vascularization’s grade of the mass 
and the onset of the complications are useful parameters which offer to the obstetrics the 
choice of caesarean section in consideration of the fetal pulmonary maturity  
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App.14 
 
PRENATAL DIAGNOSIS OF ARTHROGRYPOSIS          
 
Minerva Ginecol. 2007 Apr;59(2):201-2. 
 
Abstract 
Arthrogryposis, is an uncommon congenital syndrome clinically characterized by the 
occurrence of joint contractures of variable etiology that start prenatally. This disease 
may result from no apparent hereditary causes (neuropathic, for example) or may be the 
result of hereditary factors (myopathic form, for example). Ultrasound diagnosis depends 
on observation of scant or absent motion of fetal extremities. Prognosis depends on the 
specific etiology of the contractures. We report 4 cases of prenatal diagnosis of 
Arthrogryposis. 
 
Introduction 
Arthrogryposis is an uncommon congenital syndrome clinically characterized by multiple 
joint contractures that progressively deform child osteo-skeletal, without other congenital 
anomalies and with a relatively regular intelligence. When this presentation is in 
association with other congenital anomalies, it is defined arthrogryposis multiplex 
congenita (AMC) that develops in utero and may be related to any of a heterogeneous 
group of disorders (table1). The incidence of arthrogryposis is in relation to the reported 
incidence of AMC and that varies from one on 3000-10 000 live births. Over 150 
different etiologies have been described but most cases show a neurogenic  form of 
arthrogryposis; less often it is a primary muscle disease. It is  possible a connection with 
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autosomal trisomy, especially with 18 trisomy, about 4%. About pathological aspects all 
forms are thought to result from fetal akinesia and the causes of this may be extrinsic 
factors (oligohydramnios,  amniotic bands or uterine fibroids) or primary condition of  
CNS and PNS. 
We report 4 cases of prenatal diagnosis of Arthrogryposis and discussing counselling and 
management of this variable disease. 
                                                            
 
Clinical series 
Case1 
A 35 years-old Caucasian woman, gravida III,  was referred to our unit at 24 weeks of 
gestation.  The ultrasonography examination of the fetal head didn’t reveal the cavum 
septum pellucidum as in cases of corpus callosum hypoplasia/agenesis; the third ventricle 
was turned up and it was slightly expanded; also bilateral ventriculomegaly was noted. 
During the examination we didn’t observe fetal movements and we noted fixed extended 
knees. Bilateral clubfoot were present. Fetus biometry and the remaining anatomy were 
seen as regular. A diagnosis of arthrogryposis was suspected.  Other anomalies were not 
observed. 
Case2 
A 29 years-old Caucasian woman, gravida I, was referred to our unit at 20 week of 
gestation for an ultrasonography control. The  trans–abdominal ultrasound examination  
showed a fetus affected  by  distal arthrogryposis. Bilateral clubfoot were present and 
bothe hands were constantly closed; the  movements of other joints were regular. 
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Subcutaneous edema of the neck, thorax and abdomen were observed. Fetal biometry  
and amniotic fluid quantity were regular. Regular fetal fluximetries were indicative of a 
normal feto-placental hemodynamics. Other anomalies were not observed. The final 
diagnosis was distal arthrogryposis. The infant presented also inguinal hernia. 
Case 3 
A 31 years-old Caucasian woman, gravida III, was referred to our unit at 33 weeks of 
gestation because previous fetus affected by bilateral clubfoot and arthrogryposis. 
Ultrasound examination showed a pregnancy in evolution complicated by arthrogryposis. 
Fetus showed constantly lower limbs in the typical position as “rifle barrel” (costant 
extension of legs and thighs). Both feet were in a regular position but plantar images 
showed a good curvature. Upper limbs showed a constant position in flexion and hands 
were constantly closed (half–closed). Fetal biometry was reduced of 12 days. Amniotic 
fluid quantity was regular. Other anomalies were not observed. From the situation we 
suspected arthrogryposis. 
Case 4 
A Caucasian  woman  was referred to our unit at 28 week of gestation for a routine 
examination. The ultrasound examination showed a fetus affected by arthrogryposis. 
During all the time there were poor fetal rolling movements. Thighs were fixed in 
extension  (rifle barrel). No movements of knees and upper limbs. Left hand was in 
forced flexion while right hand was fixed with forearm fixed on thorax. Stomach and  
external genitalia were not observed. Fetal biometry was bigger than 9 days; Amniotic 
fluid was increased with largest vertical pocket of  111mm and 158 in cm2. 
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Discussion and conclusion 
 
Arthrogryposis deforms joints determining non progressive contractures caused by the 
shortening of the flexor muscles. These joints  contractures (distant segments of  the 
limbs are the most frequently affected) are typical of this disease and can be monolateral 
or bilateral. Arthrogriposis is an uncommon congenital disease characterized by multiple 
joint contractures that deform child osteo-skeletal apparatus, encountered in 
approximately one on 3000-10 000 live births. Its prenatal echographic diagnosis is quite 
difficult. Usually these syndromes are discovered in III trimester, even if prenatal 
diagnosis of severe forms is possible in II trimester. Echographic diagnosis is possible 
only after a long time that interested limbs maintained an anomalous position. It is always 
needed to practise fetal karyotype and cardio ultrasonography.  Some forms are 
particularly severe, other have only poor joints movements. It is very important  a 
particular study of the outcome (autopsy after abortus or tissutal biopsy in live births) and 
a genetic advising  to characterize the type of arthrogriposis and to estimate the 
recidivous risk. 
In case of precocious prenatal diagnosis it is necessary to offer to parents the possibility 
to stop pregnancy (TOP). In the remaining cases it is indicated an orthopaedic 
examination with precocious physiotherapy that, in the first months, can give an 
important improvement. Surgical management can be requested later to line up ankylosis 
corner but the movement is rarely improved. 
Ultrasound markers derived from an anomalous position of limbs with evidence of 
multiplex  joints contractures. Lower limbs can be fixed in extension,  in crossed-limb 
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pattern or always flexed. The foot is usually twisted  in equine variety. Upper limbs are 
typically internally rotated at the shoulders that appear in adduction, extended at the 
elbows, and flexed and deviated ulnarly at the wrists. Hands are usually closed as fist. 
Sometimes hips  are in luxation and can be slightly flexed. Knees are extended and often 
there is bilateral pes equinovarus. At the end we can see a scoliotic  spine and an 
hypoplasia of the leg muscles. In the severe forms fetus is still. Frequent is 
polihydramnios and CNS anomalies recur in 10% of cases (hydrocephalus, 
poroencephalia, agenesis of corpus callosus, microcephalia, Dandy.Walker syndrome, 
etc.). 
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 Table 1 Anomalies associated with arthrogryposis multiplex 
congenita 
Organ system
 
 Abnormality   
 Maxillofacial Craniosynostosis, mandibulofacial dysostosis,  
Micrognathia, macrostomia, decreased TMJ mobility,  
Microphthalmia;, 
Facial diplegia (Moebius’syndrome),  
Klepper-Feil syndrome,  
Low set ears, hagh arched palate, cleft palate, 
Loss of sopraglottic tone, deficient laryngeal musculature 
Poor gag reflex, poor suck reflex, dysphagia, esophageal dysfunction 
Shoulder Sprengel’s deformity 
CNS and spine Cortical brain atrophy, microgyra, Hydrocephalus, 
Loss of spinal anterior horn cells, 
Vertebral anomalies, spina bifida, saral agenesis, scoliosis, kyphosis, 
Myelomenigocele 
Cardiovascular system Petent ductus arteriosus 
Aortic stenosis 
Coarctation of the aorta 
Respiratory system Tracheoesophageal fistula 
Hypoplastic lungs 
Restrictive lung disease from scoliosis 
Aspiration pneumonitis chronc lung disease 
Gastointestinal system Esophageal dysfunction 
Gastroesophageal reflux 
Genitourinary system Fusion or absence of the kidneys 
Renal calculi 
Cryptorchidism, scrotal and labial defects 
Absence of the vagina/uterus 
Hypospadias 
Abdomen Hinguinal hernias 
Extremities Absence of patellas 
Syndactylism 
Constriction bands 
Clinodactyly 
Muscle atrophy 
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Case 1 and 2 
 
 
Case 3 and 4 
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PLACENTA, PRECLAMPSIA  and INFECTION  
 
Congenital toxoplasmosis causes blindness and mental retardation. In the United States, 
up to 85% of women of childbearing age are susceptible to infection with the 
Toxoplasma gondii parasite, which causes toxoplasmosis. Up to 50% of T gondii 
infections are transmitted by ingesting undercooked meat, making toxoplasmosis one of 
the most clinically significant food-borne diseases in pregnant women.Toxoplasma 
infection is usually asymptomatic or induces mild, nonspecific symptoms. Primary 
infection of pregnant women with the parasite Toxoplasma gondii results in infections of 
the unborn by transplacental transmission in about 50% of the cases and it may cause 
serious fetal effects, but it can be treated, thus reducing the risk of fetal malformations. 
The Italian National Health Service supports screening for toxoplasmosis in pregnancy. 
When a seroconversion occurs (2–3/1000 pregnancies), the standard treatment is 
administration of spiramycin (9106 units day until delivery). (1) Spiramycin has an 
intracellular toxoplasmocidal activity; moreover, like other macrolides, it inhibits protein 
synthesis by binding the large (50S) subunit of bacterial ribosomes, causing the growing 
polypeptide chain to dissociate from the ribosome. (2) 
Some authors had empirically observed that patients treated throughout gestation for 
toxoplasma infection seldom developed pregnancy-induced hypertension (PIH) and 
showed that antibiotic treatment during pregnancy can reduce the incidence of PIH, thus 
opening new perspectives in its prevention and therapy. (3) There are some evidence that 
infection can play a role in the pathogenesis of PIH [4-5]. 
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The results of Todros et al (3) suggest that long-lasting spiramycin treatment during 
pregnancy lowers the risk of developing PIH, probably by preventing the onset of 
infections that could complicate pregnancy. These findings open new perspectives in the 
prevention of PIH. 
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However, larger prospective studies are required to support the hypothesis that infection 
plays a role in the pathogenesis of some hypertensive disorders of pregnancy and, 
ultimately, a randomized trial is required to justify antibiotic treatment as a preventive 
strategy in clinical practice. Starting to this presuppost we now stay evaluating our date 
bases; between 1995 and 2006, 542 mother-child pairs were counselled 
in our department for suspected toxoplasmosis. Repetition of serologyand reinterpretation 
of the serological profi le (of all previous results) revealed a false-positive rate of 90% 
obtained in previous IgM tests and a seroconversion rate of 12% (63/542). We are 
studing the 63 patient with seroconversion receiving spiramycin and 200  low-risk 
women who did not take any antibiotic during pregnancy.  We stay evaluating also the 
role of  this therapy on a possible anemic state in prevention of onset of preeclampsia. 
Waiting the results we had printed our uncertainty about the benefi ts of prenatal 
treatment of toxoplasmosis. 
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App. 15  Screening for toxoplasmosis in pregnancy. 
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Preeclampsia, pregnancy complications and low concentrations of 
protein Z. 
 
Inherited thrombophilias are a heterogenous group of conditions which have been 
implicated in a variety of pregnancy complications. Evidence is mounting that implicates 
these inherited disorders in a range of pregnancy outcomes, including recurrent 
miscarriage, late fetal loss, preeclampsia, abruptio placentae, and intrauterine growth 
restriction. Although the prevalence of these complications is approximately 8% in the 
general population, their presence is associated with a significantly increased recurrence 
risk  The most commonly identified inherited thrombophilias consist of Factor V Leiden 
and the prothrombin gene mutation G20210A. Rarer inherited thrombophilic conditions 
include deficiencies of protein S, C and antithrombin. More recently, deficiency of 
protein Z has been linked to pregnancy complications, including preterm delivery and 
Preclampsia. Clinical manifestations often are associated with the presence of more than 
one inherited thrombophilia, consistent with their multigenic nature. Some, but not all, 
studies investigating the use of heparin to prevent adverse pregnancy outcome have 
demonstrated a benefit. Protein Z, a vitamin K-dependent plasma protein, has an 
important role in the regulation of the coagulation cascade. Protein Z deficiency has been 
associated with unexplained pregnancy loss and adverse pregnancy outcome in patients 
with thrombophilia. Several studies were conducted to determine if preeclampsia (PE), 
small for gestational age (SGA), and fetal demise are associated with changes in maternal 
plasma concentrations of protein Z.  PE, but not SGA or fetal demise, is associated with a 
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significantly lower maternal median plasma concentration of protein Z than normal 
pregnancy, and a high rate of protein Z deficiency is observed in patients with PE and 
fetal demise. 
Antenatal administration of heparin to prevent pregnancy complications has shown 
promise in small studies, but a randomized, placebo-controlled trial is necessary to 
determine whether heparin administration is beneficial in preventing adverse pregnancy 
outcome. 
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In the evaluation of women with fetal loss, and during the study of levels of protein Z, we 
found a variant of protein Z for a new mutazion of the protein Z gene associated with 
very low protein levels in women with fetal loss.  
 
App.16 
 
A new mutation within Protein Z gene is associated with very low 
protein levels in women with fetal  loss. 
 
 
Protein Z levels were measured in 124 women with  unexplained fetal losses and 
compared with those of  104 parous controls. Seven out 124 ( 5.6%) cases and 5 out 104 
(4.8%) controls showed PZ levels under the 5th percentile (0.52 μg/ml ). Intron C G-42A 
gene variant was also investigated and found  in 5  (71.4%,) cases and 21 [20.2%, 
Fisher Exact test p= 0.008; OR: 9.88 (95%CI: 2.03-47.1)] controls . In addition, 2 
patients with PZ levels under the 2.5 percentile carried  a new missense mutation  within 
the exon 8 causing the substitution of a hydrophobic residue (Leu) with a hydrophilic one 
(Arg) in the trypsin-like serine protease domain.  
Gene variant intron C G-42A of protein Z is significantly associated with the occurrence 
of fetal loss . A new missense sporadic  mutation within  the exon 8 is described in a 
patient. with very low protein Z levels. 
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    Protein Z (PZ) is a vitamin K-dependent glycoprotein regulating coagulation cascade 
because of protein Z-dependent protease inhibitor (1).   Reduced circulating levels of PZ 
have been suggested to play a role in the occurrence of bleeding (2) and deep vein 
thrombosis (3,4) and in early, (5) as well as  late fetal losses,  (6) although data about this 
issue  are conflicting  (7) . We recently (8) found in a cohort of patients with a 
documented venous thrombosis that the prevalence of PZ levels below the 5.0 (0.52 
μg/ml) or the 2.5 percentile of controls (0.47 μg/ml) was higher in these patients (10.2 % 
and 8.7%, respectively) than in controls (4.1%; OR: 2.7 [95% C.I.: 1.2-7.3] and 2.0%; 
OR: 4.6 [95% C.I.: 1.5-13.9], respectively). A series of variants naturally occurring 
within the PZ gene locus were investigated in that setting of patients, and PZ levels were 
found to be associated with the intron C G-42A and the intron F G79A polymorphisms. 
    Among a group of women previously (7) investigated for  otherwise unexplained fetal 
losses, 7/124 ( 5.6%) showed PZ levels under the 5th percentile ( i.e. 0.52 μg/ml ), 
calculated   in  a control group formed by 104 parous women with at least one uneventful 
pregnancy and no fetal loss. Five (4.8%, p: ns) out the 104 controls showed PZ levels 
under the 5th percentile. Therefore, we decided to investigate, by direct sequencing, 
whether PZ gene polymorphisms or sporadic mutations could be present in these 7 cases ( 
mean age + SD: 33.1+4.3 yrs ) compared to  104 controls (mean age + SD : 37+5.8 yrs).  
       Informed consent was obtained from all the subjects. Institutional Review Board 
(IRB) approval was obtained by local Ethics Commette.  Women with known causes of 
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thrombophilia (FV Leiden FII A20210 mutations, natural anticoagulants deficiency or 
antiphospholipid antibodies)  were not considered, as previously described (7) . 
Blood samples were collected into vacuum plastic tubes containing 3.8% trisodium 
citrate and centrifuged at 2,000 g for 15 min to obtain platelet-poor plasma. It was frozen 
and stored in small aliquots at -70 °C until tested. Protein Z plasma levels were evaluated 
by means of an enzyme-linked immunosorbant assay (Asserachrom Protein Z, 
Diagnostica Stago, Asnières, France). DNA was extracted from peripheral blood 
leukocytes according to standard protocols.[8] Amplifications of regions of PZ gene 
containing the intron A g-103a (intron 1; dbSNP#: rs17880587),  intron F g79a (intron 6; 
dbSNP#: rs17882561)and e intron C 42bp (g-42a)polymorphisms,  were achieved as 
previously described (8). The significance of the difference in observed genotypes  
between the groups was tested using the χ- squared  analysis . Odds Ratios (ORs) and 
95% Confidence Intervals (CI) were calculated. Two (28.6%) cases and 18 (17.3%) 
controls were heterozygous for the  intron A G -103A  mutation; AA genotype was not 
observed in cases,  whereas it was present in 3  (2.9%, p >0.05) controls. Genotype AG 
for the Intron F G79A gene variant was observed in 3 (42.9%) cases  and 32 (30.8%, p 
>0.05) controls; AA genotype was not observed in cases and  was present in 5  (4.8%) 
controls.  As far as Intron C G-42A gene variant is concerned, 5  (71.4%,) cases and 21 
[20.2%, Fisher Exact test p= 0.008; OR: 9.88 (95%CI: 2.03-47.1)] controls showed 
genotype AG, while no case and 5 (4.8%) controls carried the AA genotype . 
 In addition,  2 patients  carried  a new missense mutation  within the exon 8 (T14928C,  
accession number AF 440358) causing the substitution of a Leucine  with a Proline in the 
trypsin-like serine protease domain of the protein.  PZ levels in these patients were 0.25 
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and 0.40 μg/ml, respectively , that means below the 2.5 percentile ( 0.49 μg/ml) of the 
controls. It is known that leucine is one of the aminoacids that prefers alpha-helics and 
that proline disrupts secondary structure since side chain cannot form H-bond (see:  
www.eng.uci.edu).  This residue is highly conserved among different species. Among the 
controls, no woman carried this mutation. More interestingly, this mutation was not 
found in 197 patients  with deep vein thrombosis or in 197 age-matched controls 
previously investigated (8). This new sporadic mutation within the PZ gene could explain  
the very low PZ levels in our patients. In addition,  the Intron C G-42A  gene variants is 
associated with the occurrence of pregnancy losses in our small sample of patients. 
Further studies are needed.  
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FETAL LOSS and ECTOPIC PREGNANCY 
Ectopic pregnancy continues to be one of the most common gynecologic emergencies 
and is the leading cause of pregnancy-related first-trimester death in the United States. 
The rate of ectopic pregnancy continues to rise because of increases in the incidences of 
its risk factors. However, improved modalities of early diagnosis and treatment have 
reduced both mortality and morbidity of this condition.Evaluating women with fetal loss, 
we discovery three women with a particular type of ectopic pregnancy, a cervical 
pregnancy. Cervical pregnancy is a rare form of ectopic pregnancy in which the 
blastocyst implants and grows within the cervical canal. Cervical pregnancy occurs in 1% 
of all extrauterine gestations. The incidence varies from 1/1000 to 1/18 000 
pregnancies,.This condition has been associated with a high morbidity rate and, in the 
past, frequently led to hysterectomy as a life-saving procedure. Actually the conservative 
treatment with preoperative bilateral angiographic uterine artery embolization 
(BUAE) followed by curettage is a considered a valid approach. On the basis of these 
considerations, we present a study describing a series of 3 cases of viable cervical 
pregnancy diagnosed by TV-US and treated by means of BUAE and subsequent uterine 
curettage, underlining the safety of the technique but also its potential risk. 
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 App. 17 Is uterine artery embolization for cervical ectopic pregnancy always safe? 
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PLACENTA, PRECLAMPSIA, ANEMIA 
 
 
Intrauterine growth restriction (IUGR) is frequently associated with preeclampsia and is 
thus an important cause of maternal-fetal mortality and morbidity. (1) The disease is 
usually caused by uteroplacental vascular insufficiency (2) and results in chronic fetal 
hypoxia. As such, local tissue hypoxia in the placental bed has been proposed as the 
mechanism limiting trophoblast invasion into the spiral arteries.(3) Although maternal 
anemia may be linked to adverse pregnancy outcomes, the placenta is often enlarged, 
with increased angiogenesis in the fetal-placental vessels, to preserve gas transfer and 
fetal growth (4) whit uterine artery blood flow often normal. (5) Some authors shown that 
interstitial invasion of extravillous trophoblast into uterine tissues is increased in anemia 
and reduced in preeclampsia.(6) 
To further explore the relationship between tissue oxygenation and extravillous 
trophoblast invasion into the walls of uterine spiral arteries, the same authors studied 
intramural and endovascular trophoblast invasion in full-thickness placental bed biopsies 
at the time of cesarean hysterectomy in women whose pregnancies had been complicated 
by anemia or early-onset preeclampsia with IUGR or in normal pregnancies requiring 
intrapartum hysterectomy. Their data suggest that uteroplacental vascular insufficiency is 
due to excessive trophoblast apoptosis within the walls of spiral arteries rather than as a 
result of local hypoxic conditions inside the placental bed. They found that early-onset 
preclampsia with IUGR is characterized by reduced invasion of the spiral arteries by 
extravillous (intramural) trophoblast. This disease is associated with a doubling in the 
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frequency of apoptosis and a halving in the mean lumen area of the spiral arteries. By 
contrast, maternal anemia displayed opposite findings, with increased numbers of 
infiltrating trophoblast cells, a similar frequency of apoptosis, and increased vasodilation 
of the spiral arterial lumens, compared with control subjects. In anemic women was 
observed an increased endovascular trophoblast invasion; during maternal anemia, 
increased invasion and further dilation of the lumens of spiral arteries by the invading 
trophoblast may be an adaptive response designed to increase oxygen transfer toward the 
placenta and fetus. (7) Previous studies have shown increased numbers of proliferating 
cells within placental villi and an alteration in the structure and density of peripheral 
gasexchanging villi to favor gaseous exchange in anemia.(8) 
Kadyrof et al revealed that adaptive processes in placentas of anemic women are not 
confined to placental villi but include maternal enhanced oxygen delivery at the level of 
the spiral arteries. With a deeper invasion8 and a further dilation of the uterine spiral 
arteries (in this study), more blood and thus more oxygen can be delivered toward the 
placenta and fetus. By contrast, there are opposite findings in the placental bed of women 
with early-onset preclampsia and IUGR, with fewer cells invading the walls of spiral 
arteries and an increased frequency of  apoptosis of intramural trophoblast. Anemia is 
characterized by a normal partial pressures of oxygen of arterial blood but low oxygen 
conten and is described as a clinical entity of systemic tissue hypooxygenation. (9) The 
increased invasion seen in anemia challenges the concept of trophoblast invasion being 
limited in preclampsia by local tissue hypoxia. Indeed, mild anemia may be 1 
straightforward mechanism by which trophoblast invasion could be augmented in women 
at risk of this disease. 
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To support and to confirm on clinical level the result of the study of Kadyrov we have 
evaluated the incidence of preclampsia in a group of women with thalassemic trait.  
 
App. 18 
Incidence of preclampsia in a group of pregnant women with thalassemic-
trait 
 
Introduction 
Hypertension occurs in 5-8% of all pregnancies and may be complicated by 
preeclampsia. Preeclampsia is a complex clinical syndrome with insufficiently clear 
pathophysiology based on the damage of the vascular endothelium. As a result of this, 
generalized endothelial disruption in preeclampsia, a multiorgan dysfunction, can 
develop, most frequently reflected in the clinical presentation with haematological and 
renal damage and with a disordered function of the liver and central nervous system. 
Preeclampsia is a syndrome defined by hypertension (PA>140/90mmHg), that may be 
associated with proteinuria (>300mg/24h) and edema in pregnant women with previously 
normal blood pressure. This gestational complication occur in about 5-10% of 
pregnancies and with placental abruption, intrauterine growt restriction (IUGR) and 
intrauterine fetal death (IUFD) is the most common gestational vascular complication 
(Younis 2003). Preeclampsia is associated with maternal mortality and is the second 
cause of maternal death after thromboembolic complications. The etiology of 
preeclampsia is unknown, although much of the literature has focused on the degree of 
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trophoblastic invasion by the placenta, but also local environmental and iron deficience 
are associated. Infact, during the hipoxyc fase of placental development some trascriction 
factors releasing callicrein, erythropoietin, endotelian growht factor, HIF 1α (hipoxyc 
factor) were produced (Safran 2003). HIF 1α is the promoter of production of TGF β3 
that is the inhibitor of trophoblastic differentation. This is an adaptative response to 
hipoxia that is increased in the early-onset preeclampsia (Rajakumaz 2006). However, 
preclampsia is associated with increased production of HIF 1α, TGF β3 and ROS, just 
us in altitude and in condition of hipoxya (Solevmanlon 2005). Some studies have 
disclosed that the iron supplementation in preeclamptic pregnancies increased the 
production of  ROS, that are responsible of pathophisiology of  preeclampsia (Scholl 
2005). The hemoglobinopathies are a heterogeneous group of single-gene disorders that 
includes the structural hemoglobin variants and the thalassemias. More than 270 million 
people worldwide are heterozygous carriers of hereditary disorders of hemoglobin, and at 
least 300,000 affected homozygotes or compound heterozygotes are born each year 
(Angastiniotis 1998). The most common hemoglobinopathies are sickle cell disease and 
thalassemias. Sickle cell disease refers to a group of autosomal recessive disorders 
involving abnormal hemoglobin (hemoglobin S). The distorted red cells lead to increased 
viscosity, hemolysis, and anemia and a further decrease in oxygenation; it can cause 
repeated vasoocclusive crises with interruption of normal perfusion and function of 
several organs, including the spleen, lungs, kidneys, heart, and brain. Adults with Hb SS 
are functionally asplenic, having undergone autosplenectomy by adolescence. Absence of 
the spleen contributes to the increased incidence and severity of infection in patients with 
sickle cell disease. The most significant threat to patients with sickle cell disease is acute 
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chest syndrome that is characterized by a pulmonary infiltrate with fever that leads to 
hypoxemia and acidosis. The infiltrates are not infectious in origin but rather are due to 
vasoocclusion from sickling or embolization of marrow from long bones affected by 
sickling (Duffy 2004). The diagnosis of sickle cell disease is made by hemoglobin 
electrophoresis. In the homozygous form, nearly all the hemoglobin is Hb S with small 
amounts of Hb A2 and Hb F. Heterozygous sickle cell trait (Hb AS) is identified by a 
larger percentage of Hb A and an asymptomatic course. Solubility tests (Sickledex) alone 
are inadequate for diagnosis because they cannot distinguish between the heterozygous 
AS and homozygous SS genotypes. Sickle cell disease is associated with increased 
pregnancy complications, and urinary tract infection (American college of Obstetricians 
and Gynecologists 1993). Is may involve poor maternal nutrition, compromised uterine 
blood flow and placental infarction; endometritis is increased in women with sickle cell 
disease: cesarean section is the greatest risk factor for postpartum endometritis (Monga 
1993). The thalassemias represent a wide spectrum of hematologic disorders that are 
characterized by a reduced synthesis of globin chains, resulting in microcytic anemia. 
Many different molecular mechanism lead to thalassemia in populations from different 
areas of the world (Kazazian 1990). Alpha-thalassemia usually results from a gene 
deletion of two or more copies of the four α-globin genes. Deletion of one α-globin gene 
is clinically unrecognizable, and laboratory testing yields normal results. Deletion of two 
α-globin genes causes α-thalassemia trait, a mild asymptomatic microcytic anemia: 
individuals with these chromosomal abnormalities are referred to as carriers and are at an 
increased risk for having a child with a more severe form of thalassemia caused by 
deletion of three or four copies of the α-globin gene (α-thalassemia major). 
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 Alpha-thalassemia trait is common among individuals of Southeast Asian, African, and 
West Indian descent. Alpha-thalassemia major (Hb Bart’s) results in the absence of α-
globin (--/--); this is associated with hydrops fetalis, intrauterine death, and preeclampsia 
(Davies 2000). Hemoglobin H disease usually is associated with mild to moderate 
hemolityc anemia. Althought alpha-thalassemia also may occour as a result of a gene 
mutation. In this case, the genes are present but the function is abnormal. 
Number of Globin 
Genes 
Genotype Description Clinical Features 
4              αα/αα Normal Normal 
3              α -/αα Heterozygous  α+-
thalassemia 
Homozygous α+-
thalassemia 
Asymptomatic 
2              α -/α – 
             αα/-- 
Homozygous α+-
thalassemia 
Heterozygous  α°-
thalassemia 
Mild anemia 
1              α -/-- α+-thalassemia/ α°-
thalassemia 
Hb H disease 
Hemolytic anemia 
0              --/-- Homozygous  α°-
thalassemia 
Hb Bart’s disease  
Hydrops fetalis 
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Beta-thalassemia is caused by a mutation in the β-globin gene that causes deficient or 
absent β-chain production, resultin in absence of Hb A. Individuals who are heterozygous 
for this mutation have β-thalassemia minor. Those who are homozygous have β-
thalassemia major (Cooley’s anemia) or a mild form called thalassemia intermedia. β-
thalassemia major is characterized by severe anemia with resultant extramedullary 
erythropoiesis, delayed sexual development, and poor growht. Elevated levels of Hb F in 
individuals with β-thalassemia major partially compensate for the absence of Hb A; 
however, death usually occurs by age 10 years unless treatment is begun early with 
periodic blood transfusions. With transfusion, the severe anemia is reversed and 
extramedullary erythropoiesis is suppressed. β-thalassemia minor often occurs in 
association with Hb S (Serjeant 2001). β-thalassemia minor is common in individuals of 
Mediterranean, Asian, Middle Eastern, Hispanic, and West Indian descent, with various 
grade of severity, depending on the amount of β-chain production. The diagnosis of 
thalassemias is made by hemoglobin electroforesis. 
The World Health Organization has suggested a cut-off value of <6.8 mmol/l in the 
definition of anemia in pregnancy (World Health Organization 1972). In a population of 
unselected pregnant women there exists an inverse association between the women’s 
hemoglobin concentration and the newborn’s birth weight, which means that high 
hemoglobin levels are associated with low birth weight (Murphy 1986). High hemoglobin 
concentrations of >9 mmol/l increase blood viscosity, which may reduce placental 
perfusion and, there by, the nutrition of the fetus, resulting in low birth weight (Staer 
1995). Infact, preeclampsia and eclampsia are characterized by inadequate hemodilution, 
and these disorders are associated with low birth weight of the newborns; however, 
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anemic pregnancies decreased the rate of preeclampsia. Recently a study by Kadyrov 
compared pathological examination of 19 placentas: from 8 women with anemia, from 6 
women with severe early-onset preeclampsia and from 5 controls, to compare trophoblast 
invasion into spiral arteries and relate these findings to trophoblast apoptosis. Trophoblast 
invasion into spiral arteries was severely impaired in preeclamptic pregnancies, with an 
increased trophoblast apoptosis and  a reduced spiral artery lumen. On the contrary, 
trophoblast invasion into spiral arteries was increased in anemic pregnancies, with a 
similar trophoblast apoptosis and an increased spiral artery lumen. Infact, in preeclampsia 
the hypoxia is driving reduced invasion; by contrast, during maternal anemia, increased 
invasion and further dilation of the lumens of spiral arteries by the invading trophoblast 
may be an adaptive response designed to increase oxygen transfer toward the placenta 
and fetus (Kadyrov 2005). 
Several studies demonstred that the rate of preeclampsia is decreased in anemic 
pregnancies because trophoblast invasion into spiral arteries is increased in anemic 
pregnancies and severely impaired in preeclamptic pregnancies (Kadyrov 2003). Our 
purpose is to determine the incidence of preeclampsia in pregnancies complicated by 
hemoglobinopathies to evaluate if hemoglobinopathies is a protective factor preventing 
the development of preclampsia. 
MATERIALS AND METHODS 
In the period between 1993 and 2006, 290 patients with thalassemia trait were followed 
at our Ambulatory of High Risk Pregnancy. Subjects were screened at the prenatal 
diagnosis for thalassemia using chorionic villi obtained by chorionic villus sampling 
(CVS) at 9-13 weeks of gestation. All patient with thalassemia trait were enrolled in our 
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study to evalue maternal and neonatal outcome; the follow-up was centred about the 
incidence of preeclampsia, with screening for blood pressure, proteinuria, edema, abitual 
and actual weight. Were excluded from follw-up patients with fetus affected at prenatal 
diagnosis for failure of pregnancy. Moreover all patient who miscarried, in spite of the 
fetus was healty at prenatal diagnosis, were exclused. To test this hypothesis, we studied 
a cohort of 219 pregnant women and 553 low-risk women who did not take prenatal 
invasive diagnosis, but were enrolled at the time of prenatal ultrasonograpic screening of 
nuchal translucency. The diagnosis of preeclampsia was determined by increased blood 
pressure accompanied by proteinuria. Preclampsia was defined as blood pressure > 
140/90 mmHg on two or more occasions, occurring after 20 weeks of gestational age. . 
Proteinuria is defined as the urinary escretion of 0,3 g protein or greater in a 24 hour 
specimen. 
 
RESULTS     
290 CVS for thalassemia, 50 fetus (17,2%) resulted positive at the molecular diagnosis of 
Thalassemia and pregnancy falled. Of the 240 women with thalassemia trait, 8 patients 
(3,3%) were exclused for miscarriage, 13 women (5,4%) lost during follow-up. 
Therefore, a total of 219 patients (75,5% of 290 women) with thalassemia trait but fetus 
healty at prenatal diagnosis were inclused in our study. Our purpose was to determine the 
rate of preeclampsia for evalue the association between preeclampsia and thalassemia. 
Forthyeight (8.6%) women in the control group developed PIH compared with five 
(2,2%) in the case group. The odds of developing the disease were significantly lower 
 205
in the treated subjects  (P<0.001). The patients with preeclampsia delivered with cesarean 
section and gestational age at delivery was between 36 and 41 weeks. Birth weight was 
between 2880 ±870g. Of  the 219 patients, 6 (2,7%) had alone edema without 
hypertension or proteinuria: 5 women (83,3%) are delivered with cesarean section 
between 38 and 40 weeks of gestation, alone a patient (16,6%) with vaginal delivery at 
38 week. Of the 219 patients, 6 (2,7%) had proteinuria and hypertension without edema 
or edema with hypertension without proteinuria: three cases of proteinuria with 
hypertension (50%) and delivery through cesarean section between 38 and 40 weeks and 
three cases of edema with hypertension (50%) ; of these three cases, two women (66,6%) 
are delivered with cesarean section between 35 and 37 weeks and alone a women 
(33,3%) with vaginal delivery at 39 week of gestation. Birth weight was between 1750g 
and 3750g. Of the 6 patient, alone a women(16,6%) with edema and hypertension had 
antihypertensive therapy: she is delivered at 35 week of gestation with cesarean section 
and birth weight was 1750g. Finally, of the 219 patients, 3 (1,3%) had gestational 
hypertension, that occurs after 20 week of gestation in a woman previously normal blood 
pressure. 2 of 3 patients (66,6%) had antihypertensive therapy until delivery; on the 
contrary, a patient (33,3%) not had therapy. All three patients are delivered through 
cesarean section between 37 and 40 weeks and birth weight was between 2750g and 
4100g.  
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DISCUSSION 
Our study confirm on clinical level the data of Kadyrov showing a protective factor  
deriving from anemic state in pregnancy with decreases of the incidence of preeclampsia 
and of the other gestational vascular complications. Infact, the rate of preeclampsia in 
women with thalassemia trait was four fold low. There is an inverse relationship between 
preeclampsia and anemia because trophoblast invasion into spiral arteries was severely 
impaired in preeclamptic pregnancies, that the hypoxia is driving reduced invasion; on 
the contrary, trophoblast invasion into spiral arteries was increased in anemic pregnancies 
as an adaptive response designed to increase oxygen transfer toward the placenta and 
fetus (Kadyrov 2005). On the other hand, is very important a management of these 
disorders for maternal and neonatal outcome. 
Preeclampsia predispose to potientially lethal complications such as abruptio placentae, 
acute renal failure, cerebral hemorrhage, disseminated intravascular coagulation (CID) 
and circulatory collapse (Chesley 1984). They also weigh heavily in fetal and neonatal 
morbidity and mortality. Much of the neonatal mortality is attributable to premature 
delivery, miscarriage and intrauterine growth restriction (IUGR) that is necessary for the 
obstetrician to provide meticulous surveillance of fetal growht and well-being, including 
the biophysical profile, nonstress test, amniotic fluid volume measurement, and Doppler 
velocimetry of fetal vessels (Resnik 2002). Although absence or reversal of end-diastolic 
flow in the umbilical artery is suggestive of poor fetal condition, normal umbilical 
Doppler flow is rarely associated with significant morbidity and likely represents a 
constitutionally small fetus (Ott 2000). Therapy of preeclampsia consists in fetal and 
maternal evaluation: fetal evaluation consists of nonstress tests, biophysical profiles, 
 207
daily fetal movement assesment, ultrasound examination with Doppler velocimetry to 
evalue amniotic fluide and intrauterine growht restriction; hospitalization is often initially 
recommended for women with new-onset preeclampsia (Report of the National High 
Blood Pressure Education 2000). Maternal evaluation consists primarily of frequent 
evaluation for worsening preeclampsia. Initial laboratory tests consist of evaluation of 
platelet count, liver enzymes, and renal function and a 12-hour to 24-hour urine 
collection for protein; infact, the two main goals of management of women with 
preeclampsia are prevention of seizures or eclampsia and control of hypertension. The 
data support the use of magnesium sulfate to prevent seizures in women with severe 
preeclampsia or eclampsia (Witlin 1998), during that fetal bradycardia frequently occurs. 
Antihypertensive therapy is generally recommended for women wiht preeclampsia and 
alfametildopa and nifedipin are the two agents most commonly used for this purpose; 
diuretics and inhibitors-ACE are strictly not recommended (Cunningham 2001).  
The decision to deliver a patient with preeclamspia must balance both the maternal and 
fetal risks and delivery represents the final therapy of this desorder. If maternal and fetal 
conditions are stables the pregnancy can continue to term. If maternal conditions fall off 
but fetal conditions are stables, since 34 week of gestation women can deliver after 
therapy with corticosteroids to induce pulmonary maturity. Induction of labor with 
cesarean delivery in women with severe preeclampsia remote from term is convenient if 
fetal conditions fall off (Nassar 1998).  Much of the obstetric research in the past several 
decades has been directed at findings ways to prevent preeclampsia and eclampsia. 
Recent studies have focused on low-dose aspirin, antioxidant therapy and calcium 
supplementation. Most evidence suggests that low-dose aspirin therapy is of little, if any, 
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benefit in preventing preeclampsia in low-risk women: 60-150 mg/daily (Heyborne 
2000). Recently, antioxidant therapy with 1,000 mg per day of vitamin C and 400 mg per 
day of vitamin E has shown promise in preventing preeclampsia (Chappell 1999). While 
preeclampsia is a gestational vascular complication that gets well with delivery, 
hemoglobinopathies are disorders of hemoglobin that not get well with delivery. If both 
parents are determined to be carriers, genetic counseling is recommended. A complete 
blood count (CBC) is the appropriate initial laboratory test with determination of mean 
corpuscolar volume (MCV): infact, patients who have a low MCV (less than 80 fl) may 
have one of the thalassemia traits and are candidates for hemoglobin electroforesis. Beta- 
thalassemia is associated with elevated Hb F and elevated Hb A2 levels (more than 3.5%). 
Neither hemoglobin electroforesis nor solubility testing can identify individuals with alfa-
thalassemia trait; only molecular genetic testing can identify this condition. Prenatal 
diagnostic testing for alfa and beta-thalassemia is possible if the mutations and deletions 
have been previously identified in both parents. These DNA-based tests can be performed 
using chorionic villi obtained by chorionc villus sampling (CVS) at 10-12 weeks of 
gestation to early characterize fetus affected by disorder of hemoglobin. 
The course of pregnancy in women with the alfa-thalassemia trait is not significantly 
different from that of women with normal hemoglobin. Pregnancy in women with beta-
thalassemia major is extremely rare; initially this was because delay of growth and sexual 
development and early death in untreated patients prevented reproduction. After the 
introduction of transfusion therapy in the 1960s, pregnancy was still uncommon because 
of infertility (secondary to hypothalamic dysfunction and anovulation caused by 
hemosiderin deposition) (Jensen 1995). Since the introduction of hypertransfusion and 
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iron chelation therapy with deferoxamine, several reports have documented favorable 
pregnancy outcomes. However, pregnancy is recommended only for those with normal 
cardiac function who have had prolonged hypertransfusion therapy to maintain 
hemoglobin levels at 10 g/dL and iron chelation therapy with deferoxamine (Aessopos 
1999). Fetal growth should be monitored with serial ultrasonography and the mode of 
delivery should be individualized. Beta-thalassemia minor usually causes mild 
asymptomatic anemia and pregnancy outcome is favorable. No differences are noted in 
perinatal outcomes such as low Apgar scores, congenital malformations, or perinatal 
mortality (Sheiner 2004). Pregnancy in women with sickle cell disease is associated with 
an increased risk of morbidity and mortality because the combination of underliyng 
hemolytic anemia and multiorgan dysfunction associated with this disorder: patients have 
increased risk for preterm labor, premature rupture of membranes, antepartum 
hospitalization and postpartum infection (Sun 2001). The most common cause of 
recurrent morbidity in Hb SS disease is painful crises and hydroxyurea has been shown to 
reduce the frequency of painful crises but is not recommended during pregnancy because 
it is teratogenic. Opiates and oxygen are can replace hydroxyurea, on the other hand is 
necessary a multidisciplinary approach to evalue painful crises (Rees 2003). Pregnant 
patients with sickle cell disease need increased prenatal folic acid supplementation: 4mg 
per day. There is no consensus regarding the use of transfusion to lower the percentage of 
Hb S to approximately 40% while simultaneously raising the total hemoglobin 
concentration to about 10 g/dL. Prophylactic transfusion is associated with a decreased 
risk for painful crises and severe anemia, but no differences are observed for pregnancy 
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outcome (Koshy 1988). Such as thalassemias and preeclampsia, the mode of delivery 
should be individualized. 
Our results suggest that anemic state of pregnant women is a protective factor verus the 
onset of preclampsia and in the future a possible treatment possible with iron chelant or 
absence or minor administration of iron during pregnancy can reduce the incidence of 
PIH, thus opening new perspectives in its prevention and therapy. 
 
 
 
REFERENCES 
 
 
1)  Aessopos A, Karabatsos F, Farmakis D, Katsantoni A, Hatziliami A, Youssef J, et al. 
Pregnancy in patients with well-treated beta-talassemia: outcome for mothers and 
newborn infants. Am J Obstet Gynecol 1999; 180: 360-5. 
 
2) American college of Obstetricians and Gynecologists. Hemoglobinopathies in 
pregnancy. Washington: The college; 1993. Technical Bulletin No.: 185. 
 
3) Angastiniotis M, Modell B. global epidemiology of hemoglobin disorders. Ann N Y 
Acad Sci 1998; 850: 251-69.  
 
4) Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, et al. Effect of 
antioxidants on the occurrence of preeclampsia in women at increased risk: a 
randomised trial. Lancet 1999; 354: 810-816. 
 
5) Chesley LC. History and epidemiology of preeclampsia-eclampsia. Clin Obstet and 
Gynecol 1984; 27: 801-820. 
 
6) Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC III, Hauth JC, Wenstrom KD. 
Hypertensive disorders in pregnancy. In: Williams obstetrics. 21st ed. New York: 
McGraw-Hill, 2001: 567-618. 
 
7) Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for 
sickle cell disease and thalassemia: a systematic review with supplementary research. 
Health Technol Assess 2000; 4: i-v, 1-99. 
 
 211
8) Duffy TP. Hematologic aspects of pregnancy. In: Burrow GN, Duffy TP, Copel JA, 
editors. Medical complications during pregnancy. 6th ed. Philadelphia (PA): Elsevier 
Saunders; 2004: p. 69-86.  
 
9) Jensen CE, Tuck SM, Wonke B. Fertility in beta thalassemia major: a report of 16 
pregnancies, preconceptual evaluation and a review of the literature. Br J Obstet 
Gynecol 1995; 102: 625-9. 
 
10) Heyborne KD. Preeclampsia prevention: lessons from the low-dose aspirin therapy 
trials. Am J Obstet Gynecol 2000; 183: 523-528. 
 
11) Kadyrov M, Schmitz C, Black S, Kaufmann P, Huppertz B. Preeclampsia and 
maternal anaemia display reduced apoptosis and opposite invasive phenotypes of 
extravillous trophoblast. Placenta 2003; 24: 540-8. 
 
12) Kadyrov M, John CP, Kingdom MD, Huppertz B. Divergent trophoblast invasion 
and apoptosis in placental bed spiral arteries from pregnancies complicated by maternal 
anemia and early-onset preeclampsia/intrauterine growt restriction. Am j of Obstet & 
Gynecol 2005; 194: 557-63. 
 
13) Kazazian HH Jr. The thalassemia syndromes: molecular basis and prenatal diagnosis 
in 1990. Semin Hematol 1990; 27: 209-28.  
 
14) Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell 
transfusions in pregnant patients with sickle cell disease. A randomized cooperative 
study. N Engl J Med 1988; 319: 1447-52. 
 
15) Monga M, Oshiro BT. Puerperal infections. Semin Perinaltol 1993; 17: 426-31. 
 
16) Murphy JF, Newcombe RG, O’Riordan J, Coles EC, Pearson JF ( 1986) Relation of 
haemoglobin levels in the first and second trimesters to outcome of pregnancy. Lancet 1: 
992-994. 
 
17) Nassar AH, Adra AM, Chakhtoura N, Gomez-Marin O, Beydoun S. Severe 
preeclampsia remote from term: labor induction or elective cesarean delivery? Am J 
Obstet Gynecol 1998; 179: 1210-1213. 
 
18) Ott WJ. Intrauterine growht restriction and Doppler ultrasonography. J Ultrasound 
Med 2000; 19: 661-5. 
 
19) Rajakumaz A, Doty K, Daftary A, Markovic N, Conrad KP. Expression of von 
Hippel Lindau (pVHL) Protein Placentae from Normal Pregnant Women and Women 
with Preeclampsia. Placenta 2006; 27: 411-21. 
 
 212
20) Rees DC, Olujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines 
for the management of the acute painful crisis in sickle cell disease. British Committee 
for Standards in Haematology General Haematology Task Force by the Sickle Cell 
Working Party. Br J Haematol 2003; 120: 744-52. 
 
21) Report of the National High Blood Pressure Education Program Working Group on 
High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: s1-s22. 
 
22) Resnik R, MD. Intrauterine growth restriction. Obstet and gynecol. 2002; 99: 490-
496. 
 
23) Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing 
pathway. J Clin Invest 2003; 111: 779-83. 
 
24) Scholl TO. Iron status during pregnancy: setting the stage for mothe and infant. Am 
J Clin Nutr 2005; 81: 1218s-22s. 
 
25) Serjeant GR, Serjeant BE. Sickle cell disease. 3rd ed. New York (NY): Oxford 
University Press; 2001.  
 
26) Sheiner E, Levy A, Yerushalmi R, Katz M. Beta-thalassemia minor during 
pregnancy. Obstet Gynecol 2004; 103: 1273-7. 
 
27) Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S et al. Molecular 
evidence of Placental Hypoxia in preeclampsia. J Clin Endocrinol Metab 2005; 90: 4299-
308. 
 
28) Staer P, Alam MA, Wadsworth I, Welch A ( 1995) Relation between maternal 
haemoglobin concentration and birth weight in different ethnic groups. Br Med J 310: 
489-491. 
 
29) Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: 
twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet 
Gynecol 2001; 184: 1127-30. 
 
30) Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. 
Obstet Gynecol 1998; 92: 883-889. 
 
31) World Health Organization ( 1972) Nutritional anaemias. Technical report series no. 
503, pp 1-29. 
 
32) Younis JS md, Samueloff A md. Gestational vascular complications. Best practice & 
Research Clinical Haematology. 2003; 16: 135-151. 
 
Submission will be in process. 
 213
